

# CITATION REPORT

List of articles citing

**Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies**

**DOI: 10.1007/s00270-006-0062-3**

**CardioVascular and Interventional Radiology, 2007, 30, 6-25.**

**Source:** <https://exaly.com/paper-pdf/43079536/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
658	Principles of tumor embolotherapy and chemoembolization. 35-43		
657	Repeated courses of transarterial embolization with polyvinyl alcohol particles: 'long life elixir' in a cirrhotic patient with unresectable hepatocellular carcinoma. <b>2007</b> , 19, 329-32		4
656	Ablative and catheter-delivered therapies for colorectal liver metastases (CRLM). <b>2007</b> , 33 Suppl 2, S64-75		14
655	Chemoembolization of hepatocellular carcinoma with drug eluting beads. <b>2007</b> , 47, 157-8; author reply 159		11
654	Gelatine sponge particles: handling characteristics for endovascular use. <b>2007</b> , 10, 257-60		57
653	Management of hepatocellular carcinoma. <b>2007</b> , 11, 305-21		17
652	[Update on chemoinfusion and chemoembolization treatments]. <i>Der Radiologe</i> , <b>2007</b> , 47, 1097-106, 1108.5		6
651	Transarterial chemoembolization (TACE) for inoperable intrahepatic cholangiocarcinoma. <i>CardioVascular and Interventional Radiology</i> , <b>2007</b> , 30, 1156-65	2.7	68
650	A phase II study of pemetrexed in patients with advanced hepatocellular carcinoma. <b>2008</b> , 26, 381-6		8
649	Correlation of multislice CT and histomorphology in HCC following TACE: predictors of outcome. <i>CardioVascular and Interventional Radiology</i> , <b>2008</b> , 31, 768-77	2.7	44
648	Necrosis and apoptosis in hepatocellular carcinoma following low-dose versus high-dose preoperative chemoembolization. <i>CardioVascular and Interventional Radiology</i> , <b>2008</b> , 31, 1133-40	2.7	10
647	[Embolotherapy: principles and indications]. <i>Der Radiologe</i> , <b>2008</b> , 48, 73-95; quiz 96-7	1.5	9
646	Early detection of liver cancer: diagnosis and management. <b>2008</b> , 10, 60-6		17
645	The modern use of radiofrequency energy in surgery, endoscopy and interventional radiology. <b>2008</b> , 40, 204-210		22
644	Synergistic antitumor effects of transarterial viroembolization for multifocal hepatocellular carcinoma in rats. <b>2008</b> , 48, 1864-73		33
643	Fatal ischemic acute pancreatitis complicating trans-catheter arterial embolization of small hepatocellular carcinoma: do the risks outweigh the benefits?. <b>2008</b> , 49, 149-52		9
642	Selective transarterial chemoembolization of advanced hepatocellular carcinomas: a reasonable palliative option. <b>2008</b> , 40, 3179-81		6

641	Drug-eluting polymer implants in cancer therapy. <b>2008</b> , 5, 775-88		43
640	Interventional radiology in liver cancer. <b>2008</b> , 20, 185-193		
639	TACE versus TAE as therapy for hepatocellular carcinoma. <b>2008</b> , 8, 1623-41		65
638	Evidence-based diagnosis and locoregional therapy for hepatocellular carcinoma. <b>2008</b> , 2, 761-84		11
637	Combined approach to hepatocellular carcinoma: a new treatment concept for nonresectable disease. <b>2008</b> , 8, 1743-9		64
636	Transarterial chemoembolization in the management of primary and secondary liver tumors. 74-91		
635	The current practice of transarterial chemoembolization for the treatment of hepatocellular carcinoma. <b>2009</b> , 10, 425-34		113
634	Unresectable hepatocellular carcinoma: serial early vascular and cellular changes after transarterial chemoembolization. <b>2009</b> , 250, 324-6		5
633	The efficacy and safety of percutaneous microwave coagulation by a new microwave delivery system in large hepatocellular carcinomas: four case studies. <b>2009</b> , 25, 392-8		16
632	Transarterial injection of (131)I-lipiodol, compared with chemoembolization, in the treatment of unresectable hepatocellular cancer. <b>2009</b> , 50, 871-7		32
631	P.119 Etude de cytotoxicité in vitro des différents anticancéreux candidats à la chimioembolisation des carcinomes hépatocellulaires. <b>2009</b> , 33, A78		
630	Initial data on a novel endovascular radiofrequency catheter when used for arterial occlusion in liver cancer. <b>2009</b> , 41, 104-108		3
629	Transarterielle Chemoembolisation bei hepatozellulärem Karzinom [neue Entwicklungen]. <b>2009</b> , 4, 330-339		1
628	A case of acute ischemic duodenal ulcer associated with superior mesenteric artery dissection after transarterial chemoembolization for hepatocellular carcinoma. <i>CardioVascular and Interventional Radiology</i> , <b>2009</b> , 32, 367-70	2.7	6
627	Unusual severe complication following transarterial chemoembolization for metastatic malignant melanoma: giant intrahepatic cyst and fatal hepatic failure. <i>CardioVascular and Interventional Radiology</i> , <b>2009</b> , 32, 361-4	2.7	6
626	Targeted constitutive activation of signal transducer and activator of transcription 3 in human hepatocellular carcinoma cells by cucurbitacin B. <b>2009</b> , 63, 635-42		58
625	Review on transarterial chemoembolization in hepatocellular carcinoma: palliative, combined, neoadjuvant, bridging, and symptomatic indications. <b>2009</b> , 72, 505-16		108
624	Safety and feasibility of outpatient transcatheter hepatic arterial embolization for hepatocellular carcinoma. <b>2009</b> , 20, 203-8		11

623	Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009. <b>2009</b> , 10, 1111-8		325
622	Current management of hepatocellular carcinoma. <b>2009</b> , 93, 885-900, viii		45
621	Arterial chemoembolization/embolization and early complications after hepatocellular carcinoma treatment: a safe standardized protocol in selected patients with Child class A and B cirrhosis. <b>2009</b> , 20, 896-902		31
620	Pilot study of transarterial chemoembolization with pirarubicin and amiodarone for unresectable hepatocellular carcinoma. <b>2009</b> , 32, 238-44		8
619	Minimally invasive techniques in management of hepatic neuroendocrine metastatic disease. <b>2009</b> , 32, 200-15		19
618	Bleeding gastric ulcer after prophylactic coiling of transarterial chemoembolization. <b>2010</b> , 44, 588-91		2
617	Transarterial chemoembolization in patients with hepatocellular carcinoma and renal insufficiency. <b>2010</b> , 44, e171-7		29
616	Intra-arterial therapies for hepatocellular carcinoma: where do we stand?. <i>Annals of Surgical Oncology</i> , <b>2010</b> , 17, 1234-46	3.1	70
615	Long-term survival and prognostic factors after pulmonary metastasectomy in hepatocellular carcinoma. <i>Annals of Surgical Oncology</i> , <b>2010</b> , 17, 2795-801	3.1	45
614	Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. <i>CardioVascular and Interventional Radiology</i> , <b>2010</b> , 33, 41-52	2.7	1076
613	MDCT versus MRI assessment of tumor response after transarterial chemoembolization for the treatment of hepatocellular carcinoma. <i>CardioVascular and Interventional Radiology</i> , <b>2010</b> , 33, 532-40	2.7	96
612	Controlled release and antitumor effect of pluronic F127 mixed with cisplatin in a rabbit model. <i>CardioVascular and Interventional Radiology</i> , <b>2010</b> , 33, 135-42	2.7	15
611	Bland embolization in patients with unresectable hepatocellular carcinoma using precise, tightly size-calibrated, anti-inflammatory microparticles: first clinical experience and one-year follow-up. <i>CardioVascular and Interventional Radiology</i> , <b>2010</b> , 33, 552-9	2.7	76
610	Computed analysis of three-dimensional cone-beam computed tomography angiography for determination of tumor-feeding vessels during chemoembolization of liver tumor: a pilot study. <i>CardioVascular and Interventional Radiology</i> , <b>2010</b> , 33, 1235-42	2.7	72
609	Minimally invasive image-guided therapy for inoperable hepatocellular carcinoma: What is the evidence today?. <b>2010</b> , 1, 167-81		16
608	Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. <b>2010</b> , 4, 439-74		825
607	Transarterial chemoembolization, transarterial chemotherapy, and intra-arterial chemotherapy for hepatocellular carcinoma treatment. <b>2010</b> , 37, 89-93		34
606	[Percutaneous and intra-arterial treatment of hepatocellular carcinoma]. <b>2010</b> , 52, 399-413		0

605	Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort study. <b>2010</b> , 116, 1305-14	147
604	Is it time to reconsider the BCLC/AASLD therapeutic flow-chart?. <b>2010</b> , 102, 868-76	23
603	Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States. <b>2010</b> , 16, 262-78	306
602	Surgical treatment of hepatocellular carcinoma: expert consensus statement. <b>2010</b> , 12, 302-10	77
601	Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus conference. <b>2010</b> , 12, 321-2	1
600	Renal failure in patients with hepatocellular carcinoma and ascites undergoing transarterial chemoembolization. <b>2010</b> , 30, 77-84	31
599	Impact of evidence-based medicine on the treatment of patients with unresectable hepatocellular carcinoma. <b>2010</b> , 31, 493-501	27
598	Diagnosis and management of hepatocellular carcinoma: results of a consensus meeting of The Ottawa Hospital Cancer Centre. <i>Current Oncology</i> , <b>2010</b> , 17, 6-12	2.8 6
597	Transarterial Radioembolization with Yttrium-90 for Regional Management of Hepatocellular Cancer: The Early Results of a Nontransplant Center. <b>2010</b> , 76, 1079-1083	1
596	An evidence-based multidisciplinary approach to the management of hepatocellular carcinoma (HCC): the Alberta HCC algorithm. <b>2010</b> , 24, 643-50	28
595	Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study. <b>2010</b> , 15, 1198-204	73
594	Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. <b>2010</b> , 28, 3994-4005	306
593	Multiparametric imaging of tumor response to therapy. <b>2010</b> , 256, 348-64	178
592	Hepatocellular carcinoma: the place of new medical therapies. <b>2010</b> , 3, 259-67	8
591	Transarterial embolisation of hepatocellular carcinoma with doxorubicin-eluting beads: single centre early experience. <b>2010</b> , 6, e7	15
590	Treatment of hepatocellular carcinoma with intra-arterial injection of radionuclides. <b>2010</b> , 7, 41-9	41
589	Iodized oil pleural effusion in a patient previously treated with transarterial chemoembolization for hepatocellular carcinoma. <b>2010</b> , 138, 193-5	6
588	Drug-eluting beads for liver embolization: concentration of doxorubicin in tissue and in beads in a pig model. <b>2010</b> , 21, 259-67	89

587	Characterizing clinicopathological findings of transarterial chemoembolization for Wilms tumor. <b>2010</b> , 183, 1138-44	6
586	Arterial patency after repeated hepatic artery bland particle embolization. <b>2010</b> , 21, 522-6	28
585	Role of surgical resection for pulmonary metastasis of hepatocellular carcinoma. <b>2010</b> , 70, 295-300	24
584	Treatment of early hepatocellular carcinoma: How to predict and prevent recurrence. <b>2010</b> , 42 Suppl 3, S249-57	19
583	The intermediate hepatocellular carcinoma stage: Should treatment be expanded?. <b>2010</b> , 42 Suppl 3, S258-63	46
582	Future perspectives in hepatocellular carcinoma. <b>2010</b> , 42 Suppl 3, S302-9	55
581	Liver cancer: from molecular pathogenesis to new therapies: summary of the EASL single topic conference. <b>2010</b> , 52, 296-304	36
580	Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocellular carcinoma: a meta-analysis. <b>2010</b> , 52, 380-8	221
579	Which transarterial therapy is best for hepatocellular carcinoma?--the evidence to date. <b>2010</b> , 53, 588	12
578	[Nonsurgical management of hepatocellular carcinoma]. <b>2010</b> , 14, 469-73	
577	Chapter 5: Transcatheter arterial chemoembolization. <b>2010</b> , 40, 96-112	3
576	Spinal cord injury subsequent to transcatheter arterial chemoembolization in patients with hepatocellular carcinoma. <b>2010</b> , 42, 67-70	17
575	Neuroradiologie et radiologie digestive interventionnelles. <b>2010</b> , 6, 47-50	
574	Correlation between tumor perfusion and lipiodol deposition in hepatocellular carcinoma after transarterial chemoembolization. <b>2010</b> , 21, 1841-6	29
573	Guidelines for establishing a quality improvement program in interventional radiology. <b>2010</b> , 21, 617-25	26
572	Liver, gastrointestinal, and cardiac toxicity in intermediate hepatocellular carcinoma treated with PRECISION TACE with drug-eluting beads: results from the PRECISION V randomized trial. <i>American Journal of Roentgenology</i> , <b>2011</b> , 197, W562-70	5.4 136
571	Outcome of supraselective transarterial chemoembolization in patients with hepatocellular carcinoma. <b>2011</b> , 46, 201-10	4
570	Advances in regional chemotherapy of the liver. <b>2011</b> , 8, 1057-69	15

569	The use of transarterial chemoembolization in the treatment of unresectable hepatocellular carcinoma: a response to the Cochrane Collaboration review of 2011. <b>2011</b> , 22, 1693-6	24
568	Elution characteristics of doxorubicin-loaded microspheres differ by drug-loading method and microsphere size. <b>2011</b> , 22, 361-8	7
567	Hepatocellular necrosis, apoptosis, and proliferation after transcatheter arterial embolization or chemoembolization in a standardized rabbit model. <b>2011</b> , 22, 1606-12	13
566	Randomised controlled trial of lipiodol transarterial chemoembolisation with or without amiodarone for unresectable hepatocellular carcinoma. <b>2011</b> , 43, 905-11	7
565	Induction Chemotherapy for Hepatocellular Carcinoma. <b>2011</b> , 237-250	
564	DC Bead embolic drug-eluting bead: clinical application in the locoregional treatment of tumours. <b>2011</b> , 8, 153-69	54
563	Risk factors for the leakage of chemotherapeutic agents into systemic circulation after transcatheter arterial chemoembolization of hepatocellular carcinoma. <b>2011</b> , 27, 431-6	4
562	Potential risk factors for the reactivation of the replication of hepatitis B and C viruses after transcatheter arterial chemoembolization of hepatocellular carcinoma. <b>2011</b> , 27, 554-9	9
561	Comparative analysis of the safety and efficacy of transcatheter arterial chemoembolization and yttrium-90 radioembolization in patients with unresectable hepatocellular carcinoma. <b>2011</b> , 22, 1697-705	81
560	Water-soluble polyvinyl alcohol microspheres for temporary embolization: development and in vivo characteristics in a pig kidney model. <b>2011</b> , 22, 212-9	10
559	Complications of percutaneous procedures. <b>2011</b> , 29, 802-10	5
558	Experience Using Doxorubicin-Loaded DC Beads During Hepatic Chemoembolisation. <b>2011</b> , 35, 172-179	
557	Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. <b>2011</b> , 47, 2117-27	390
556	High-intensity focused ultrasound combined with transarterial chemoembolization for unresectable hepatocellular carcinoma: long-term follow-up and clinical analysis. <b>2011</b> , 80, 662-9	28
555	Validation of preclinical multiparametric imaging for prediction of necrosis in hepatocellular carcinoma after embolization. <b>2011</b> , 55, 1034-40	32
554	EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization. <b>2011</b> , 55, 1309-16	253
553	Embolization of hepatocellular carcinoma with drug-eluting beads: new insight into the biologic effects of tumor ablation. <b>2011</b> , 55, 1169-70	4
552	Imaging characteristics following 90yttrium microsphere treatment for unresectable liver cancer. <b>2011</b> , 55, 111-8	32

551	Comparative study of cisplatin and epirubicin in transcatheter arterial chemoembolization for hepatocellular carcinoma. <b>2011</b> , 41, 303-9		14
550	Hepatic arterial embolization complicated by acute cholecystitis. <b>2011</b> , 28, 252-7		10
549	Transarterial Chemoembolization of Child-A hepatocellular carcinoma: drug-eluting bead TACE (DEB TACE) vs. TACE with cisplatin/lipiodol (cTACE). <b>2011</b> , 17, CR189-95		51
548	Multidisciplinary Canadian consensus recommendations for the management and treatment of hepatocellular carcinoma. <i>Current Oncology</i> , <b>2011</b> , 18, 228-40	2.8	44
547	Arterial embolization hyperthermia using As <sub>2</sub> O <sub>3</sub> nanoparticles in VX2 carcinoma-induced liver tumors. <b>2011</b> , 6, e17926		22
546	Who could Benefit from Chemoembolisation?. <b>2011</b> , 125-135		
545	Primary Malignant Neoplasms of the Liver. <b>2011</b> , 681-703		4
544	Predicting survival in patients with hepatocellular carcinoma treated by transarterial chemoembolisation. <b>2011</b> , 34, 196-204		46
543	Chemoembolization for hepatocellular carcinoma. <b>2011</b> , 46, 105-14		4
542	Trans-arterial chemoembolization as a therapy for liver tumours: New clinical developments and suggestions for combination with angiogenesis inhibitors. <b>2011</b> , 80, 40-53		55
541	[Experience using doxorubicin-loaded DC Beads] during hepatic chemoembolisation]. <b>2011</b> , 35, 172-9		3
540	Transarterial chemoembolisation: effect of selectivity on tolerance, tumour response and survival. <i>European Radiology</i> , <b>2011</b> , 21, 1719-26	8	43
539	A novel transcatheter arterial infusion chemotherapy using iodized oil and degradable starch microspheres for hepatocellular carcinoma: a prospective randomized trial. <b>2011</b> , 46, 359-66		27
538	Current concepts in transarterial chemoembolization of hepatocellular carcinoma. <b>2011</b> , 36, 677-83		18
537	Safety profile of sequential transcatheter chemoembolization with DC Bead—results of 237 hepatocellular carcinoma (HCC) patients. <i>CardioVascular and Interventional Radiology</i> , <b>2011</b> , 34, 774-85	2.7	102
536	Combination therapy of transcatheter arterial chemoembolization and arterial administration of antiangiogenesis on VX2 liver tumor. <i>CardioVascular and Interventional Radiology</i> , <b>2011</b> , 34, 824-32	2.7	21
535	A woman with remotely treated pancreas cancer and new abdominal pain: a discussion of evaluation and management. <b>2011</b> , 42, 236-40		0
534	Efficacy of selective transarterial chemoembolization in inducing tumor necrosis in small (. <b>2011</b> , 53, 1580-9		187



533	Transarterial therapies for hepatocellular carcinoma. <b>2011</b> , 12, 1057-73		29
532	Arterially directed therapies for hepatocellular carcinoma. <i>American Journal of Roentgenology</i> , <b>2011</b> , 197, W590-602	5-4	16
531	Transarterial chemoembolization complicated by deteriorating hepatic function. <b>2011</b> , 28, 198-201		2
530	Transcatheter intraarterial therapies: rationale and overview. <b>2011</b> , 259, 641-57		174
529	Previous chemoembolization response after transcatheter arterial chemoembolization (TACE) can predict the anti-tumor effect of subsequent TACE with miriplatin in patients with recurrent hepatocellular carcinoma. <b>2011</b> , 80, 188-94		17
528	Superselective transarterial chemoembolization for hepatocellular carcinoma: recent progression and perspective. <b>2011</b> , 81 Suppl 1, 105-10		7
527	Drug delivery embolization systems: a physician's perspective. <b>2011</b> , 8, 1071-84		14
526	Hepatic resection versus transarterial lipiodol chemoembolization as the initial treatment for large, multiple, and resectable hepatocellular carcinomas: a prospective nonrandomized analysis. <b>2011</b> , 259, 286-95		50
525	Vascular invasion in hepatocellular carcinoma: is there a correlation with MRI?. <b>2012</b> , 85, 736-44		11
524	Transarterial chemoembolization for hepatocellular carcinoma over three decades: current progress and perspective. <b>2012</b> , 42, 247-55		37
523	Transcatheter arterial chemotherapy using miriplatin-lipiodol suspension with or without embolization for unresectable hepatocellular carcinoma. <b>2012</b> , 42, 175-82		14
522	Hepatocellular carcinoma. <b>2012</b> , 366, 92; author reply 92-3		49
521	Chemoembolization practice patterns and technical methods among interventional radiologists: results of an online survey. <i>American Journal of Roentgenology</i> , <b>2012</b> , 198, 692-9	5-4	53
520	Transarterial chemoembolization for HCC in patients with extensive liver transplantation waiting times. <b>2012</b> , 63, 206-12		6
519	Transcatheter arterial chemoembolization: history for more than 30 years. <b>2012</b> , 2012, 480650		35
518	Imaging and Imaging-Guided Interventions in the Diagnosis and Management of Hepatocellular Carcinoma (HCC)-Review of Evidence. <b>2012</b> , 9, 167-77		16
517	Liver cancer: effects, safety, and cost-effectiveness of controlled-release oxycodone for pain control after TACE. <b>2012</b> , 262, 1014-21		20
516	Computed tomographic perfusion imaging for the therapeutic response of chemoembolization for hepatocellular carcinoma. <b>2012</b> , 36, 226-30		27

515	Management of HCC. <b>2012</b> , 56 Suppl 1, S75-87	438
514	Nitroglycerine use in transcatheter arterial (chemo)embolization in patients with hepatocellular carcinoma and dual-energy CT assessment of Lipiodol retention. <i>European Radiology</i> , <b>2012</b> , 22, 2193-200 <sup>8</sup>	18
513	Mortality and morbidity of hepatectomy, radiofrequency ablation, and embolization for hepatocellular carcinoma: a national survey of 54,145 patients. <b>2012</b> , 47, 1125-33	86
512	Stereotactic body radiation therapy in recurrent hepatocellular carcinoma. <b>2012</b> , 84, 355-61	132
511	An inflammation-based prognostic index predicts survival advantage after transarterial chemoembolization in hepatocellular carcinoma. <b>2012</b> , 160, 146-52	49
510	Ethiodized oil uptake does not predict doxorubicin drug delivery after chemoembolization in VX2 liver tumors. <b>2012</b> , 23, 265-73	38
509	Retrospective study on the use of different protocols for repeated transarterial chemoembolization in the treatment of patients with hepatocellular carcinoma. <b>2012</b> , 19, 434-9	7
508	Improved time to progression for transarterial chemoembolization compared with transarterial embolization for patients with unresectable hepatocellular carcinoma. <b>2012</b> , 11, 185-90	15
507	Back again to vasopressin?. <b>2012</b> , 23, 1513-5	
506	Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines. <b>2012</b> , 56, 886-92	145
505	Reply to: Do EASL and mRECIST responses have independent effects on survival in hepatocellular carcinoma patients treated with transarterial embolization? <b>2012</b> , 57, 225-226	
504	Transarterial chemoembolization in very early and early-stage hepatocellular carcinoma patients excluded from curative treatment: a prospective cohort study. <b>2012</b> , 81, 1173-8	70
503	Selective and sequential transarterial chemoembolization: survival in patients with hepatocellular carcinoma. <b>2012</b> , 81, 2290-7	11
502	Phase I study of miriplatin combined with transarterial chemotherapy using CDDP powder in patients with hepatocellular carcinoma. <b>2012</b> , 12, 127	9
501	Management of hepatocellular carcinoma with transarterial chemoembolization in the era of systemic targeted therapy. <b>2012</b> , 83, 216-24	37
500	Locoregional radiological treatment for hepatocellular carcinoma; Which, when and how?. <b>2012</b> , 38, 54-62	49
499	Liposomes and inorganic nanoparticles for drug delivery and cancer imaging. <b>2012</b> , 3, 645-56	64
498	Response rate and clinical outcome of HCC after first and repeated cTACE performed "on demand". <b>2012</b> , 57, 1258-67	100

497	Safety and feasibility of same-day discharge of patients with unresectable hepatocellular carcinoma treated with doxorubicin drug-eluting bead transcatheter chemoembolization. <b>2012</b> , 23, 1286-93.e1 <sup>22</sup>		
496	Prospective evaluation of transcatheter arterial chemoembolization (TACE) with multiple anti-cancer drugs (epirubicin, cisplatin, mitomycin c, 5-fluorouracil) compared with TACE with epirubicin for treatment of hepatocellular carcinoma. <i>CardioVascular and Interventional Radiology</i> , <b>2012</b> , 35, 1363-71	2.7	38
495	Cisplatin pharmacokinetics in nontumoral pig liver treated with intravenous or transarterial hepatic chemoembolization. <i>CardioVascular and Interventional Radiology</i> , <b>2012</b> , 35, 1467-74	2.7	1
494	Chemoembolization with doxorubicin-eluting beads for unresectable hepatocellular carcinoma: five-year survival analysis. <i>CardioVascular and Interventional Radiology</i> , <b>2012</b> , 35, 1119-28	2.7	139
493	Quality-improvement guidelines for hepatic transarterial chemoembolization. <i>CardioVascular and Interventional Radiology</i> , <b>2012</b> , 35, 765-74	2.7	54
492	Liver Cancer. <b>2012</b> , 95-119		
491	Short-term therapeutic effects of transcatheter arterial chemoembolization using miriplatin-lipiodol suspension for hepatocellular carcinoma. <b>2012</b> , 30, 735-42		12
490	Current status of hepatocellular carcinoma treatment in Japan: transarterial chemoembolization. <b>2012</b> , 32 Suppl 2, 3-13		19
489	Comparison of epirubicin-iodized oil suspension and emulsion for transcatheter arterial chemoembolization in VX2 tumor. <b>2012</b> , 2012, 961986		8
488	Antibiotic prophylaxis in transarterial therapy of hepatocellular carcinoma: a meta-analysis. <b>2012</b> , 26, 85-91		7
487	Effective therapeutic management of hepatocellular carcinoma - on the basis of a clinical case. <b>2012</b> , 16, 60-3		8
486	Interventional therapies for hepatocellular carcinoma. <b>2012</b> , 12, 79-88		23
485	Stereotactic body radiation therapy for inoperable hepatocellular carcinoma as a local salvage treatment after incomplete transarterial chemoembolization. <b>2012</b> , 118, 5424-31		223
484	Hepatic artery embolization and chemoembolization of liver tumors. <b>2012</b> , 1344-1361.e3		
483	Switching the loaded agent from epirubicin to cisplatin: salvage transcatheter arterial chemoembolization with drug-eluting microspheres for unresectable hepatocellular carcinoma. <i>CardioVascular and Interventional Radiology</i> , <b>2012</b> , 35, 555-62	2.7	21
482	Conventional transarterial chemoembolisation in combination with sorafenib for patients with hepatocellular carcinoma: a pilot study. <i>European Radiology</i> , <b>2012</b> , 22, 1214-23	8	41
481	Austrian Joint ÖGH-ÖIR-ÖHO-ASSO position statement on the use of transarterial chemoembolization (TACE) in hepatocellular carcinoma. <b>2012</b> , 124, 104-10		12
480	Locoregional drug delivery using image-guided intra-arterial drug eluting bead therapy. <b>2012</b> , 161, 338-50		87

479	Differential prognostic impact of renal insufficiency on patients with hepatocellular carcinoma: a propensity score analysis and staging strategy. <b>2012</b> , 27, 690-9		11
478	[Transarterial ablation of hepatocellular carcinoma. Status and developments]. <i>Der Radiologe</i> , <b>2012</b> , 52, 44-55	1.5	7
477	Lipiodol trans-arterial chemoembolization of hepatocellular carcinoma with idarubicin: first experience. <i>CardioVascular and Interventional Radiology</i> , <b>2013</b> , 36, 1039-46	2.7	18
476	Changes in hepatic blood flow during transcatheter arterial infusion with heated saline in hepatic VX2 tumor. <i>CardioVascular and Interventional Radiology</i> , <b>2013</b> , 36, 764-72	2.7	
475	Postembolization syndrome after hepatic transarterial chemoembolization: effect of prophylactic steroids on postprocedure medication requirements. <b>2013</b> , 24, 326-31		20
474	Hepatotoxicity after transarterial chemoembolization and transjugular intrahepatic portosystemic shunt: do two rights make a wrong?. <b>2013</b> , 24, 68-73		24
473	Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma (EPOIHCC). <b>2013</b> , 33, 327-37		52
472	A randomised phase II/III trial of 3-weekly cisplatin-based sequential transarterial chemoembolisation vs embolisation alone for hepatocellular carcinoma. <b>2013</b> , 108, 1252-9		99
471	Transarterial chemoembolization of hepatocellular carcinoma. Agents and drugs: an overview. Part 1. <b>2013</b> , 10, 679-90		22
470	[Transarterial chemoembolisation in hepatocellular carcinoma]. <b>2013</b> , 163, 123-7		3
469	A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer. <b>2013</b> , 24, 2565-2570		200
468	Transarterial therapies for hepatocellular carcinoma (HCC): a long way towards standardization. <b>2013</b> , 58, 194		3
467	Reply to: "Transarterial therapies for hepatocellular carcinoma (HCC): a long way towards standardization". <b>2013</b> , 58, 195		1
466	Metaanalysis of survival, complications, and imaging response following chemotherapy-based transarterial therapy in patients with unresectable intrahepatic cholangiocarcinoma. <b>2013</b> , 24, 1218-26		55
465	Transarterial chemoembolization for the treatment of hepatocellular carcinoma: a single center experience including 221 patients. <b>2013</b> , 25, 143-50		8
464	Transarterial chemoembolization treatment: association between multiple treatments, cumulative expenditures, and survival. <b>2013</b> , 16, 760-8		13
463	Hepatocellular carcinoma responding to superselective transarterial chemoembolization: an issue of nodule dimension?. <b>2013</b> , 24, 509-17		71
462	Transarterial chemoembolisation is not superior to embolisation alone: the recent European Association for the Study of the Liver (EASL) - European Organisation for Research and Treatment of Cancer (EORTC) guidelines. <b>2013</b> , 49, 1509-10		21

461	Position paper of the Italian Association for the Study of the Liver (AISF): the multidisciplinary clinical approach to hepatocellular carcinoma. <b>2013</b> , 45, 712-23	128
460	Effect of hepatic artery embolization on liver hypertrophy response in a rabbit liver VX2 tumor model. <b>2013</b> , 12, 622-9	4
459	Hepatic embolotherapy in interventional oncology: technology, techniques, and applications. <b>2013</b> , 68, 1-15	30
458	Result and cost of hepatic chemoembolisation with drug eluting beads in 21 patients. <b>2013</b> , 94, 53-9	9
457	Résultat et coût de la chimioembolisation hépatique avec des billes chargées chez 21 patients. <b>2013</b> , 94, 52-59	1
456	Use of Lipiodol as a drug-delivery system for transcatheter arterial chemoembolization of hepatocellular carcinoma: a review. <b>2013</b> , 88, 530-49	131
455	Transcatheter arterial embolization followed by octreotide and celecoxib synergistically prolongs survival of rabbits with hepatic VX2 allografts. <b>2013</b> , 14, 29-37	8
454	Risk factors and a predictive model for acute hepatic failure after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma. <b>2013</b> , 33, 197-202	27
453	Transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: recent progression and perspective. <b>2013</b> , 84 Suppl 1, 28-33	10
452	[Diagnosis of and therapy for hepatocellular carcinoma]. <b>2013</b> , 51, 1269-326	67
451	Sorafenib combined with transarterial chemoembolization for the treatment of advanced hepatocellular carcinoma: a large-scale multicenter study of 222 patients. <b>2013</b> , 24, 1786-1792	85
450	Sorafenib in combination with transarterial chemoembolization in Chinese patients with hepatocellular carcinoma: a subgroup interim analysis of the START trial. <b>2013</b> , 9, 403-10	21
449	Safety and efficacy of transcatheter arterial chemoembolization in the real-life management of unresectable hepatocellular carcinoma. <b>2013</b> , 13, e7070	8
448	Evaluation of transarterial chemoembolization in treating hepatocellular carcinoma. <b>2013</b> , 3, 41-46	
447	Antitumor efficacy of transcatheter arterial chemoembolization with warmed miriplatin in hepatocellular carcinoma. <b>2013</b> , 43, 942-9	18
446	Comparison of the antitumor efficacy of transcatheter arterial chemoembolization with a miriplatin-iodized oil suspension and a cisplatin-iodized oil suspension for hepatocellular carcinoma. <b>2013</b> , 43, 1071-7	8
445	Comparison of epirubicin hydrochloride and miriplatin hydrate as anticancer agents for transcatheter arterial chemoembolization of hepatocellular carcinoma. <b>2013</b> , 43, 475-80	8
444	The role of bridging therapy in hepatocellular carcinoma. <b>2013</b> , 2013, 419302	15

443	The features of extrahepatic collateral arteries related to hepatic artery occlusion and benefits in the transarterial management of liver tumors. <b>2013</b> , 2013, 535272	3
442	Transarterial embolization as neo-adjuvant therapy pretransplantation in patients with hepatocellular carcinoma. <b>2013</b> , 33, 944-9	43
441	Roles played by chemolipiodolization and embolization in chemoembolization for hepatocellular carcinoma: single-blind, randomized trial. <b>2013</b> , 105, 59-68	47
440	Treatment of (131)I-labeled anti-CD147 monoclonal antibody in VX2 carcinoma-induced liver tumors. <b>2013</b> , 30, 246-52	6
439	Morbidity and mortality following transarterial liver chemoembolization in patients with hepatocellular carcinoma and synthetic hepatic dysfunction. <b>2013</b> , 19, 164-73	56
438	Student award winner in the Ph.D. category for the 2013 society for biomaterials annual meeting and exposition, april 10-13, 2013, Boston, Massachusetts : biomaterial-mediated cancer-specific DNA delivery to liver cell cultures using synthetic poly(beta-amino ester)s. <b>2013</b> , 101, 1837-45	33
437	A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers: is it adherent to the EASL/AASLD recommendations?: an observational study of the HCC East-West study group. <b>2013</b> , 257, 929-37	337
436	Clinical significance of the thymidylate synthase, dihydropyrimidine dehydrogenase, and thymidine phosphorylase mRNA expressions in hepatocellular carcinoma patients receiving 5-fluorouracil-based transarterial chemoembolization treatment. <b>2013</b> , 6, 811-8	7
435	Transarterial chemoembolization in combination with local therapies for hepatocellular carcinoma: a meta-analysis. <b>2013</b> , 8, e68453	41
434	Drug-eluting bead transarterial chemoembolisation for unresectable hepatocellular carcinoma. <b>2013</b> ,	
433	Chloroquine promotes the anticancer effect of TACE in a rabbit VX2 liver tumor model. <b>2013</b> , 9, 322-30	23
432	Results in Hepatocellular Carcinoma. <i>Medical Radiology</i> , <b>2013</b> , 105-117	0.2 1
431	Interventional radiology in liver cancer. <b>2013</b> , 22, 20120010	
430	Transarterial chemoembolization and bland embolization for hepatocellular carcinoma. <b>2014</b> , 20, 3069-77	52
429	The efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization for primary hepatocellular carcinoma in a cohort of 487 patients. <b>2014</b> , 9, e89081	28
428	The effect of using different embolic agents on survival in transarterial chemoembolization of hepatocellular carcinoma: gelfoam versus polyvinyl alcohol. <b>2014</b> , 20, 323-9	11
427	Ginsenoside Rg3 attenuates hepatoma VEGF overexpression after hepatic artery embolization in an orthotopic transplantation hepatocellular carcinoma rat model. <b>2014</b> , 7, 1945-54	18
426	Transcatheter arterial chemoembolization therapy for patients with unresectable hepatocellular carcinoma. <b>2014</b> , 14, e25792	6

425	The diagnosis and treatment of hepatocellular carcinoma. <b>2014</b> , 111, 101-6		57
424	The ART score is not effective to select patients for transarterial chemoembolization retreatment in an Italian series. <b>2014</b> , 32, 711-6		34
423	Transarterial embolization with or without chemotherapy for advanced hepatocellular carcinoma: a systematic review. <b>2014</b> , 35, 8451-9		21
422	Transcriptional regulation of human UDP-glucuronosyltransferase genes. <b>2014</b> , 46, 421-58		70
421	Preresection transarterial chemoembolization for hepatocellular carcinoma: an experience with 23 patients. <b>2014</b> , 33, 432-9		5
420	Doxorubicin -eluting beads in the treatment of liver carcinoma. <b>2014</b> , 15, 115-20		2
419	Clinical outcomes of a cohort series of patients with hepatocellular carcinoma in a hepatitis B virus-endemic area. <b>2014</b> , 29, 820-9		37
418	Idarubicin-loaded beads for chemoembolisation of hepatocellular carcinoma: results of the IDASPHERE phase I trial. <b>2014</b> , 39, 1301-13		41
417	Editorial: IDASPHERE phase I trial for chemoembolisation for HCC - authors' reply: a necessary step for treatment optimisation and standardisation. <b>2014</b> , 40, 210-1		
416	Re-evaluating transarterial chemoembolization for the treatment of hepatocellular carcinoma: Consensus recommendations and review by an International Expert Panel. <b>2014</b> , 34, 174-83		53
415	Acute eosinophilic and neutrophilic pneumonia following transarterial chemoembolization with drug-eluting beads loaded with doxorubicin for hepatocellular carcinoma: a case report. <b>2014</b> , 88, 426-9		2
414	Transarterial therapy: an evolving treatment modality of hepatocellular carcinoma. <b>2014</b> , 20, 333-41		4
413	Safety and feasibility of same-day discharge of patients with hepatocellular carcinoma treated with transarterial chemoembolization with drug-eluting beads in a liver transplantation program. <b>2014</b> , 25, 1012-7		16
412	Predictive factors of transarterial chemoembolisation toxicity in unresectable hepatocellular carcinoma. <b>2014</b> , 46, 358-62		12
411	Safety and effectiveness of chemoembolization with drug-eluting beads for advanced-stage hepatocellular carcinoma. <i>CardioVascular and Interventional Radiology</i> , <b>2014</b> , 37, 381-7	2.7	51
410	Trends in utilization of transarterial treatments for hepatocellular carcinoma: results of a survey by the Italian Society of Interventional Radiology. <i>CardioVascular and Interventional Radiology</i> , <b>2014</b> , 37, 438-44	2.7	35
409	Treatment outcomes of transcatheter arterial chemoembolization combined with local ablative therapy versus monotherapy in hepatocellular carcinoma: a meta-analysis. <b>2014</b> , 140, 199-210		24
408	Treatment of liver tumours with yttrium radioembolisation. <b>2014</b> , 2, 165-182		2

407	Nonsurgical treatment for localized hepatocellular carcinoma. <b>2014</b> , 16, 373	11
406	Microfluidic fabrication of 6-methoxyethylamino numonafide-eluting magnetic microspheres. <b>2014</b> , 10, 742-50	15
405	Hepatocellular carcinoma: diagnosis, management, and prognosis. <b>2014</b> , 23, 289-311	49
404	Transcatheter arterial chemoembolization for advanced hepatocellular carcinoma with portal vein invasion: safety, efficacy, and prognostic factors. <b>2014</b> , 25, 32-40	38
403	Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. <b>2014</b> , 111, 255-64	349
402	Doxorubicin-eluting beads versus conventional transarterial chemoembolization for the treatment of hepatocellular carcinoma. <b>2014</b> , 29, 920-5	79
401	TACE plus sorafenib for the treatment of hepatocellular carcinoma: results of the multicenter, phase II SOCRATES trial. <b>2014</b> , 74, 947-54	51
400	Chemoembolization and radioembolization. <b>2014</b> , 28, 909-19	14
399	Epirubicin upregulates UDP glucuronosyltransferase 2B7 expression in liver cancer cells via the p53 pathway. <b>2014</b> , 85, 887-97	33
398	TACE performed in patients with a single nodule of hepatocellular carcinoma. <b>2014</b> , 14, 601	28
397	Selective internal radiotherapy (SIRT) versus transarterial chemoembolization (TACE) for the treatment of intrahepatic cholangiocellular carcinoma (CCC): study protocol for a randomized controlled trial. <b>2014</b> , 15, 311	18
396	[Transarterial ablative therapy of hepatocellular carcinoma]. <i>Der Radiologe</i> , <b>2014</b> , 54, 685-93	1.5 0
395	Transarterial therapies for primary liver tumors. <b>2014</b> , 23, 323-51	8
394	Guidelines on the use of gelatin sponge particles in embolotherapy. <b>2014</b> , 32, 242-50	31
393	Efficacy and nontarget effects of transarterial chemoembolization in bridging of hepatocellular carcinoma patients to liver transplantation: a histopathologic study. <b>2014</b> , 25, 1018-1026.e4	15
392	Aldoketoreductase family 1B10 (AKR1B10) as a biomarker to distinguish hepatocellular carcinoma from benign liver lesions. <b>2014</b> , 45, 834-43	48
391	The clinical management of hepatocellular carcinoma in the United States, Europe, and Asia: a comprehensive and evidence-based comparison and review. <b>2014</b> , 120, 2824-38	179
390	Role of Transcatheter Intra-arterial Therapies for Hepatocellular Carcinoma. <b>2014</b> , 4, S112-21	22



389	The Indian National Association for Study of the Liver (INASL) Consensus on Prevention, Diagnosis and Management of Hepatocellular Carcinoma in India: The Puri Recommendations. <b>2014</b> , 4, S3-S26	38
388	Hepatic resection associated with good survival for selected patients with intermediate and advanced-stage hepatocellular carcinoma. <b>2014</b> , 260, 329-40	282
387	Cytotoxic activity of anticancer drugs on hepatocellular carcinoma cells in hypoxic-hyponutritional culture. <b>2014</b> , 99, 745-52	6
386	Balloon-Occluded Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma: A Single-Center Experience. <b>2015</b> , 89 Suppl 2, 27-32	19
385	TIGAR regulates DNA damage and repair through pentosephosphate pathway and Cdk5-ATM pathway. <b>2015</b> , 5, 9853	40
384	Hepatocellular carcinoma in patients listed for liver transplantation: Current and future allocation policy and management strategies for the individual patient. <b>2015</b> , 21, 1543-52	24
383	Predictors of hepatic decompensation after TACE for hepatocellular carcinoma. <b>2015</b> , 2, e000032	18
382	p53 gene therapy-based transarterial chemoembolization for unresectable hepatocellular carcinoma: A prospective cohort study. <b>2015</b> , 30, 1651-6	11
381	Hepatic angiosarcoma may have fair survival nowadays. <b>2015</b> , 94, e816	17
380	Transarterial chemoembolization using gelatin sponges or microspheres plus lipiodol-doxorubicin versus doxorubicin-loaded beads for the treatment of hepatocellular carcinoma. <b>2015</b> , 16, 125-32	33
379	Hepatocellular carcinoma: From diagnosis to treatment. <b>2015</b> , 7, 1020-9	108
378	MRI visible drug eluting magnetic microspheres for transcatheter intra-arterial delivery to liver tumors. <b>2015</b> , 5, 477-88	49
377	Hepatocellular carcinoma: A comprehensive review. <b>2015</b> , 7, 2648-63	136
376	MRI Findings and Prediction of Time to Progression of Patients with Hepatocellular Carcinoma Treated with Drug-eluting Bead Transcatheter Arterial Chemoembolization. <b>2015</b> , 30, 965-73	10
375	Addition of n-butyl cyanoacrylate to classic transarterial chemoembolization may improve the radiological response in patients with hepatocellular carcinoma. <b>2015</b> , 70, 781-9	1
374	A prognostic score for patients with intermediate-stage hepatocellular carcinoma treated with transarterial chemoembolization. <b>2015</b> , 10, e0125244	30
373	Efficacy and adverse events of transcatheter arterial chemoembolization in combination with sorafenib in the treatment of unresectable hepatocellular carcinoma. <b>2015</b> , 3, 929-935	12
372	Hepatocellular carcinoma: Consensus, controversies and future directions. A report from the Canadian Association for the Study of the Liver Hepatocellular Carcinoma Meeting. <b>2015</b> , 29, 178-84	27

- 371 Drug-eluting bead transarterial chemoembolisation for unresectable hepatocellular carcinoma. **2015,**
- 370 Current and future treatments for hepatocellular carcinoma. **2015,** 21, 8478-91 112
- 369 Transarterial chemoembolization using drug eluting beads for the treatment of hepatocellular carcinoma: Now and future. **2015,** 21, 344-8 21
- 368 Role of radiotherapy in the management of hepatocellular carcinoma: A systematic review. **2015,** 7, 101-12 97
- 367 Intermediate hepatocellular carcinoma: How to choose the best treatment modality?. **2015,** 7, 1184-91 16
- 366 Transarterial approaches to primary and secondary hepatic malignancies. **2015,** 12, 481-9 28
- 365 Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma. **2015,** 15, 465 77
- 364 Minimal invasive treatments for liver malignancies. **2015,** 27, 659-667 6
- 363 Intermediate hepatocellular carcinoma: the role of transarterial therapy. **2015,** 2, 399-408 9
- 362 Post-embolization syndrome as an early predictor of overall survival after transarterial chemoembolization for hepatocellular carcinoma. **2015,** 17, 1137-44 24
- 361 Trans-arterial chemoembolization with doxorubicin-eluting particles versus conventional trans-arterial chemoembolization in unresectable hepatocellular carcinoma: A study of effectiveness, safety and costs. **2015,** 57, 496-504 10
- 360 Survival analysis of proposed BCLC-B subgroups in hepatocellular carcinoma patients. **2015,** 35, 591-600 50
- 359 Complete response at first chemoembolization is still the most robust predictor for favorable outcome in hepatocellular carcinoma. **2015,** 62, 1304-10 108
- 358 Idarubicin-loaded ONCOZENE drug-eluting embolic agents for chemoembolization of hepatocellular carcinoma: in vitro loading and release and in vivo pharmacokinetics. **2015,** 26, 262-70 26
- 357 Comparative effectiveness of hepatic artery based therapies for unresectable intrahepatic cholangiocarcinoma. **2015,** 111, 213-20 103
- 356 BCLC stage B hepatocellular carcinoma and transcatheter arterial chemoembolization: a 20-year survey by the Italian Liver Cancer group. **2015,** 35, 223-31 30
- 355 Hepatocellular carcinoma. **2015,** 94-104
- 354 Trans-arterial p53-gene-embolization with gelatin sponge microparticles for hepatocellular carcinoma with BCLC stage B: single-center experience. **2015,** 71, 99-104 9

353	Systematic review of guidelines for management of intermediate hepatocellular carcinoma using the Appraisal of Guidelines Research and Evaluation II instrument. <b>2015</b> , 47, 877-83	7
352	Chimioembolisation des carcinomes h̃patocellulaires : une vieille m̃thode au gõt du jour. <b>2015</b> , 96, 162-171	
351	Automated Quantification of Tumor Viability in a Rabbit Liver Tumor Model after Chemoembolization Using Infrared Imaging. <b>2015</b> , 185, 1877-88	6
350	Survival Outcome Between Hepatic Resection and Transarterial Embolization for Hepatocellular Carcinoma More Than 10 cm: A Propensity Score Model. <b>2015</b> , 39, 1510-8	7
349	Transarterial chemoembolization for hepatocellular carcinoma: An old method, now flavor of the day. <b>2015</b> , 96, 607-15	18
348	Balloon-occluded transarterial chemoembolization using a 1.8-French tip coaxial microballoon catheter for hepatocellular carcinoma: technical and safety considerations. <b>2015</b> , 24, 94-100	26
347	Trans-arterial chemoembolization with doxorubicin-eluting particles versus conventional trans-arterial chemoembolization in unresectable hepatocellular carcinoma: A study of effectiveness, safety and costs. <b>2015</b> , 57, 496-504	15
346	Gene expression in hepatocellular carcinoma: pilot study of potential transarterial chemoembolization response biomarkers. <b>2015</b> , 26, 723-32	14
345	Multimodal treatment of unresectable hepatocellular carcinoma to achieve complete response results in improved survival. <b>2015</b> , 17, 454-60	4
344	Hong Kong consensus recommendations on the management of hepatocellular carcinoma. <b>2015</b> , 4, 51-69	35
343	Segmental Transarterial Embolization in a Translational Rat Model of Hepatocellular Carcinoma. <b>2015</b> , 26, 1229-37	25
342	Therapeutic strategies for hepatocellular carcinoma: new advances and challenges. <b>2015</b> , 13, 219-34	17
341	Transarterial chemoembolization: modalities, indication, and patient selection. <b>2015</b> , 62, 1187-95	163
340	Hepatic Resection Improved the Long-Term Survival of Patients with BCLC Stage B Hepatocellular Carcinoma in Asia: a Systematic Review and Meta-Analysis. <b>2015</b> , 19, 1271-80	29
339	Induction of human UDP-Glucuronosyltransferase 2B7 gene expression by cytotoxic anticancer drugs in liver cancer HepG2 cells. <b>2015</b> , 43, 660-8	21
338	Development of Conventional Transarterial Chemoembolization for Hepatocellular Carcinomas in Japan: Historical, Strategic, and Technical Review. <i>American Journal of Roentgenology</i> , <b>2015</b> , 205, 764-73 <sup>5-4</sup>	24
337	Cancer therapy related complications in the liver, pancreas, and biliary system: an imaging perspective. <b>2015</b> , 6, 665-77	14
336	Ampelopsin induces apoptosis in HepG2 human hepatoma cell line through extrinsic and intrinsic pathways: Involvement of P38 and ERK. <b>2015</b> , 40, 847-54	17

335	Radioembolization with 90Y-microspheres for liver tumors. <b>2015</b> , 34, 244-257	
334	Stability of a highly concentrated solution of epirubicin for conventional transcatheter arterial chemoembolization. <b>2015</b> , 495, 956-62	0
333	Systematic review comparing the safety and efficacy of conventional and drug-eluting bead transarterial chemoembolization for inoperable hepatocellular carcinoma. <b>2015</b> , 45, 190-200	60
332	Transarterial embolization therapies for the treatment of hepatocellular carcinoma: CEPO review and clinical recommendations. <b>2015</b> , 17, 52-65	17
331	Hepatocellular Carcinoma: A Phase II Randomized Controlled Double-Blind Trial of Transarterial Chemoembolization in Combination with Biweekly Intravenous Administration of Bevacizumab or a Placebo. <b>2015</b> , 277, 903-12	46
330	[Radioembolization with (90)Y-microspheres for liver tumors]. <b>2015</b> , 34, 244-57	1
329	Les gastropathies : mise au point. <b>2015</b> , 2015, 27-35	
328	Clinical and economic impact of drug eluting beads in transarterial chemoembolization for hepatocellular carcinoma. <b>2015</b> , 40, 83-90	10
327	Transarterial chemoembolization for primary liver malignancies and colorectal liver metastasis. <b>2015</b> , 24, 149-66	13
326	Efficacy and safety of cisplatin versus miriplatin in transcatheter arterial chemoembolization and transarterial infusion chemotherapy for hepatocellular carcinoma: A randomized controlled trial. <b>2015</b> , 45, 514-22	15
325	Advanced imaging techniques in the therapeutic response of transarterial chemoembolization for hepatocellular carcinoma. <b>2016</b> , 22, 4835-47	19
324	Management of hepatocellular carcinoma: an overview of major findings from meta-analyses. <b>2016</b> , 7, 34703-51	51
323	Radiofrequency and microwave ablation in combination with transarterial chemoembolization induce equivalent histopathologic coagulation necrosis in hepatocellular carcinoma patients bridged to liver transplantation. <b>2016</b> , 5, 225-33	19
322	Treatment of Huge Hepatocellular Carcinoma Using Cinobufacini Injection in Transarterial Chemoembolization: A Retrospective Study. <b>2016</b> , 2016, 2754542	11
321	Preparation and Characterization of Irinotecan Loaded Cross-Linked Bovine Serum Albumin Beads for Liver Cancer Chemoembolization Therapy. <b>2016</b> , 2016, 1-8	5
320	Transcatheter arterial chemoembolisation (TACE) plus S-1 for the treatment of BCLC stage B hepatocellular carcinoma refractory to TACE. <b>2016</b> , 20, 468-474	4
319	The Changes of HIF-1 $\alpha$ and VEGF Expression After TACE in Patients With Hepatocellular Carcinoma. <b>2016</b> , 8, 297-302	52
318	Hepatocellular carcinoma: asphyxiate and then cook. <b>2016</b> , 3, 1-3	

317	Multiparametric human hepatocellular carcinoma characterization and therapy response evaluation by hyperpolarized (13) C MRSI. <b>2016</b> , 29, 952-60		20
316	In vitro clearance of doxorubicin with a DNA-based filtration device designed for intravascular use with intra-arterial chemotherapy. <b>2016</b> , 18, 98		9
315	Interventional radiology in the management of hepatopancreatobiliary malignancy and surgical complications. <b>2016</b> , 100-119		
314	Clinical outcomes and prognostic factors of cyberknife stereotactic body radiation therapy for unresectable hepatocellular carcinoma. <b>2016</b> , 16, 451		22
313	Multifunctional microbeads for drug delivery in TACE. <b>2016</b> , 13, 1289-300		16
312	Interventional oncology for hepatocellular carcinoma. <b>2016</b> , 40, 530-537		6
311	Comparative analysis of current guidelines for the treatment of hepatocellular carcinoma. <b>2016</b> , 3, 119-136		7
310	Single- versus Triple-Drug Chemoembolization for Hepatocellular Carcinoma: Comparing Outcomes by Toxicity, Imaging Response, and Survival. <b>2016</b> , 27, 1279-1287		10
309	Transarterial bland versus chemoembolization for hepatocellular carcinoma: rethinking a gold standard. <b>2016</b> , 200, 552-9		15
308	TAE for HCC: When the Old Way is Better than the New Ones!!!. <i>CardioVascular and Interventional Radiology</i> , <b>2016</b> , 39, 799-800	2.7	9
307	Electrochemical Effects after Transarterial Chemoembolization in Combination with Percutaneous Irreversible Electroporation: Observations in an Acute Porcine Liver Model. <b>2016</b> , 27, 913-921.e2		8
306	Progress in surgical and nonsurgical approaches for hepatocellular carcinoma treatment. <b>2016</b> , 15, 234-56		30
305	Treatment of Patients with Advanced Hepatocellular Carcinoma using Stem Cell Differentiation Stage Factors. <b>2016</b> , 72, 205-217		
304	A novel sulfamethazine-based pH-sensitive copolymer for injectable radiopaque embolic hydrogels with potential application in hepatocellular carcinoma therapy. <b>2016</b> , 7, 5805-5818		24
303	Pancreatic neuroendocrine tumors: contemporary diagnosis and management. <b>2016</b> , 44, 109-19		27
302	Reply: Which is the Best Chemotherapeutic Agent for Transarterial Chemoembolization of Hepatocellular Carcinoma?. <i>CardioVascular and Interventional Radiology</i> , <b>2016</b> , 39, 955-6	2.7	
301	Induction Chemotherapy for Hepatocellular Carcinoma. <b>2016</b> , 269-284		
300	Cost-effectiveness of doxorubicin-eluting beads versus conventional trans-arterial chemo-embolization for hepatocellular carcinoma. <b>2016</b> , 48, 798-805		34

299	Visualization of hepatic arteries with 3D ultrasound during intra-arterial therapies. <b>2016,</b>		1
298	Effect of perioperative parecoxib sodium on postoperative pain control for transcatheter arterial chemoembolization for inoperable hepatocellular carcinoma: a prospective randomized trial. <i>European Radiology</i> , <b>2016</b> , 26, 3492-9	8	18
297	Advances in transarterial therapies for hepatocellular carcinoma: is novel technology leading to better outcomes?. <b>2016</b> , 3, 109-118		2
296	Superselective Conventional Transarterial Chemoembolization for Hepatocellular Carcinoma: Rationale, Technique, and Outcome. <b>2016</b> , 27, 1269-1278		37
295	Hepatocellular carcinoma: modern image-guided therapies. <b>2016</b> , 92, 165-71		6
294	Parametric response mapping of contrast-enhanced biphasic CT for evaluating tumour viability of hepatocellular carcinoma after TACE. <i>European Radiology</i> , <b>2016</b> , 26, 3447-55	8	8
293	Clinical Significance of Multiple Pulmonary Metastasectomy for Hepatocellular Carcinoma. <b>2016</b> , 40, 380-7		22
292	Correlation of Doxorubicin Delivery and Tumor Necrosis after Drug-eluting Bead Transarterial Chemoembolization of Rabbit VX2 Liver Tumors. <b>2016</b> , 280, 752-61		27
291	Randomized Trial of Hepatic Artery Embolization for Hepatocellular Carcinoma Using Doxorubicin-Eluting Microspheres Compared With Embolization With Microspheres Alone. <b>2016</b> , 34, 2046-53		239
290	Conventional Ethiodized Oil Transarterial Chemoembolization for Treatment of Hepatocellular Carcinoma: Contemporary Single-Center Review of Clinical Outcomes. <i>American Journal of Roentgenology</i> , <b>2016</b> , 206, 645-54	5.4	13
289	ACR Appropriateness Criteria Radiologic Management of Hepatic Malignancy. <b>2016</b> , 13, 265-73		7
288	Prospective Study of Transcatheter Arterial Chemoembolization (TACE) with Ginsenoside Rg3 versus TACE Alone for the Treatment of Patients with Advanced Hepatocellular Carcinoma. <b>2016</b> , 280, 630-9		43
287	Impact of the Interval between Transarterial Chemoembolization Sessions on Survival in Patients with Unresectable Hepatocellular Carcinoma. <b>2016</b> , 27, 504-13		3
286	DC BeadM1 towards an optimal transcatheter hepatic tumour therapy. <b>2016</b> , 27, 13		26
285	Effectiveness of Transarterial Embolization of Hepatocellular Carcinoma as a Bridge to Transplantation. <b>2016</b> , 27, 39-45		13
284	Jian Pi Li Qi Decoction Alleviated Postembolization Syndrome Following Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma: A Randomized, Double-Blind, Placebo-Controlled Trial. <b>2016</b> , 15, 349-57		13
283	Treatment of Liver Tumors with Lipiodol TACE: Technical Recommendations from Experts Opinion. <i>CardioVascular and Interventional Radiology</i> , <b>2016</b> , 39, 334-43	2.7	133
282	Management strategies for hepatocellular carcinoma: old certainties and new realities. <b>2016</b> , 16, 243-56		23

281	Interventional Radiology for the Pre-transplant Patient. <b>2017</b> , 427-438	
280	Transarterial Embolization With or Without Chemotherapy: What Should Be the Indication for Patients With Hepatocellular Carcinoma?. <b>2017</b> , 35, 257-258	3
279	Transarterial Therapies for Hepatocellular Carcinoma. <b>2016</b> , 6, 27-33	34
278	Therapeutic priorities for solitary large hepatocellular carcinoma in a hepatitis B virus endemic area; an analysis of a nationwide cancer registry database. <b>2017</b> , 115, 407-416	4
277	Transarterial chemo-embolisation of hepatocellular carcinoma: impact of liver function and vascular invasion. <b>2017</b> , 116, 448-454	46
276	Adjuvant transarterial chemoembolization for patients after curative resection of hepatocellular carcinoma: a meta-analysis. <b>2017</b> , 52, 624-634	38
275	Early Sorafenib-related Biomarkers for Combination Treatment with Transarterial Chemoembolization and Sorafenib in Patients with Hepatocellular Carcinoma. <b>2017</b> , 284, 583-592	15
274	Ischemia Induces Quiescence and Autophagy Dependence in Hepatocellular Carcinoma. <b>2017</b> , 283, 702-710	30
273	Update on Embolization Therapies for Hepatocellular Carcinoma. <b>2017</b> , 19, 40	23
272	A 'degradable' poly(vinyl alcohol) iron oxide nanoparticle hydrogel. <b>2017</b> , 58, 376-385	22
271	Targeting the vasculature in hepatocellular carcinoma treatment: Starving versus normalizing blood supply. <b>2017</b> , 8, e98	54
270	Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial. <b>2017</b> , 2, 565-575	226
269	Liver transplantation for hepatocellular carcinoma: current update on treatment and allocation. <b>2017</b> , 22, 128-134	9
268	Doxorubicin Drug-Eluting Embolic Chemoembolization of Hepatocellular Carcinoma: Study of Midterm Doxorubicin Delivery in Resected Liver Specimens. <b>2017</b> , 28, 804-810	6
267	Decision Making: Intra-arterial Therapies for Cholangiocarcinoma-TACE and TARE. <b>2017</b> , 34, 92-100	25
266	Prognostic factors of sorafenib therapy in hepatocellular carcinoma patients with failure of transarterial chemoembolization. <b>2017</b> , 11, 292-299	5
265	Polymeric nanoparticles as cancer-specific DNA delivery vectors to human hepatocellular carcinoma. <b>2017</b> , 263, 18-28	40
264	New concepts in embolotherapy of HCC. <b>2017</b> , 34, 58	42

263	In Vivo Drug Delivery Performance of Lipiodol-Based Emulsion or Drug-Eluting Beads in Patients with Hepatocellular Carcinoma. <b>2017</b> , 14, 448-458		20
262	Local Arterial Therapies in the Management of Unresectable Hepatocellular Carcinoma. <b>2017</b> , 18, 67		1
261	Dexamethasone Prophylaxis to Alleviate Postembolization Syndrome after Transarterial Chemoembolization for Hepatocellular Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled Study. <b>2017</b> , 28, 1503-1511.e2		20
260	Transarterial (chemo)embolisation versus chemotherapy for colorectal cancer liver metastases. <b>2017</b> ,		0
259	Targeted Yttrium 89-Doxorubicin Drug-Eluting Bead-A Safety and Feasibility Pilot Study in a Rabbit Liver Cancer Model. <b>2017</b> , 14, 2824-2830		5
258	Radiation Therapy for Hepatocellular Carcinoma: Clinical Data. <b>2017</b> , 179-198		
257	Treatment of hepatocellular carcinoma using transarterial chemoembolization: a real-life, single-centre study from Southern Brazil. <b>2017</b> , 29, 225-230		1
256	An Update on Randomized Clinical Trials in Hepatocellular Carcinoma. <b>2017</b> , 26, 647-666		4
255	Sorafenib and 2,3,5-triiodobenzoic acid-loaded imageable microspheres for transarterial embolization of a liver tumor. <b>2017</b> , 7, 554		17
254	Transhepatic arterial infusion chemotherapy using a combination of miriplatin and CDDP powder versus miriplatin alone in the treatment of hepatocellular carcinoma: a randomized controlled trial. <b>2017</b> , 17, 322		3
253	Quality Improvement Guidelines for Transarterial Chemoembolization and Embolization of Hepatic Malignancy. <b>2017</b> , 28, 1210-1223.e3		69
252	Effects of sorafenib and cisplatin on preneoplastic foci of altered hepatocytes in fetal turkey liver. <b>2017</b> , 6, 54-62		1
251	Transarterial chemoembolization of hepatocellular carcinoma with segmental portal vein tumour thrombus. <i>European Radiology</i> , <b>2017</b> , 27, 1448-1458	8	22
250	Racial disparities in treatment and survival of hepatocellular carcinoma in native Americans and Hispanics. <b>2017</b> , 214, 100-104		5
249	Preclinical Benefit of Hypoxia-Activated Intra-arterial Therapy with Evofosfamide in Liver Cancer. <b>2017</b> , 23, 536-548		23
248	Liver and biliary damages following transarterial chemoembolization of hepatocellular carcinoma: comparison between drug-eluting beads and lipiodol emulsion. <i>European Radiology</i> , <b>2017</b> , 27, 1431-1439 <sup>8</sup>		57
247	Transarterial chemoembolization vs bland embolization in hepatocellular carcinoma: A meta-analysis of randomized trials. <b>2017</b> , 5, 511-518		41
246	Cinnamic Acid Derivatives Enhance the Efficacy of Transarterial Embolization in a Rat Model of Hepatocellular Carcinoma. <i>CardioVascular and Interventional Radiology</i> , <b>2017</b> , 40, 430-437	2.7	14



245	Expression of cluster of differentiation 151 prior to and following transcatheter arterial chemoembolization therapy in patients with hepatocellular carcinoma and its association with clinicopathological characteristics. <b>2018</b> , 15, 1133-1142	
244	[Hepatobronchial Fistula and Lung Abscess after Transarterial Chemoembolization]. <b>2017</b> , 69, 316-320	
243	Hepatic artery embolization and chemoembolization of liver tumors. <b>2017</b> , 1398-1416.e4	
242	Evaluation of CT vascularization patterns for survival prognosis in patients with hepatocellular carcinoma treated by conventional TACE. <b>2017</b> , 23, 217-222	8
241	Comparative effectiveness of different transarterial embolization therapies alone or in combination with local ablative or adjuvant systemic treatments for unresectable hepatocellular carcinoma: A network meta-analysis of randomized controlled trials. <b>2017</b> , 12, e0184597	59
240	Locoregional and systemic therapy for hepatocellular carcinoma. <b>2017</b> , 8, 215-228	46
239	Downstaging for hepatocellular cancer: harm or benefit?. <b>2017</b> , 2, 106	17
238	Hong Kong Consensus Statements for the Management of Unresectable Hepatocellular Carcinoma. <b>2018</b> , 7, 40-54	16
237	Evaluation of the Effect of Operator Experience on Outcome of Hepatic Artery Embolization of Hepatocellular Carcinoma in a Tertiary Cancer Center. <b>2018</b> , 25, 856-860	2
236	EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. <b>2018</b> , 69, 182-236	3196
235	Evaluation of Hepatocellular Carcinoma Transarterial Chemoembolization using Quantitative Analysis of 2D and 3D Real-time Contrast Enhanced Ultrasound. <b>2018</b> , 4, 035039	14
234	The impact of transarterial chemoembolization induced complications on outcomes after liver transplantation: A propensity-matched study. <b>2018</b> , 32, e13255	5
233	Liver Cancers. <b>2018</b> , 100-116	
232	Intra-arterial idarubicin_lipiodol without embolisation in hepatocellular carcinoma: The LIDA-B phase I trial. <b>2018</b> , 68, 1163-1171	6
231	Role of interventional radiology in managing pediatric liver tumors : Part 1: Endovascular interventions. <b>2018</b> , 48, 555-564	18
230	Transvascular therapy of Hepatocellular Carcinoma (HCC), status and developments. <b>2018</b> , 27, 69-80	10
229	Long-term outcome of stereotactic body radiotherapy for patients with small hepatocellular carcinoma. <b>2018</b> , 48, 701-707	14
228	Hepatocellular carcinoma treatment: ablation and arterial embolization. <b>2018</b> , 60, 156-166	1

227	Liver-directed therapy for hepatocellular carcinoma. <b>2018</b> , 43, 203-217		8
226	Prognostic Factors for Survival After Transarterial Chemoembolization Combined with Sorafenib in the Treatment of BCLC Stage B and C Hepatocellular Carcinomas. <b>2018</b> , 25, 423-429		7
225	Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study. <b>2018</b> , 3, 37-46		69
224	Systematic Review and Meta-Analysis of Posttransplant Hepatic Artery and Biliary Complications in Patients Treated With Transarterial Chemoembolization Before Liver Transplantation. <b>2018</b> , 102, 88-96		14
223	Liver resection for HCC outside the BCLC criteria. <b>2018</b> , 403, 37-44		12
222	Reply to "Comment on 'In Vivo Drug Delivery Performance of Lipiodol-Based Emulsion or Drug-Eluting Beads in Patients with Hepatocellular Carcinoma'". <b>2018</b> , 15, 336-340		1
221	Intraprocedural 3D perfusion measurement during chemoembolisation with doxorubicin-eluting beads in liver metastases of malignant melanoma. <i>European Radiology</i> , <b>2018</b> , 28, 1456-1464	8	5
220	Development of an orthotopic canine prostate cancer model expressing human GRPr. <b>2018</b> , 78, 1111		3
219	Treatment of Liver Tumors with Transarterial Chemoembolization. <b>2018</b> , 35, 350-355		1
218	Rational design of temperature-sensitive blood-vessel-embolic nanogels for improving hypoxic tumor microenvironment after transcatheter arterial embolization. <b>2018</b> , 8, 6291-6306		16
217	Transcatheter arterial chemoembolization combined with radiofrequency or microwave ablation for hepatocellular carcinoma: a review. <b>2018</b> , 5, HEP07		10
216	Interventional Radiology in Oncology. <b>2018</b> , 41-61		
215	Hepatocellular carcinoma treatment: hurdles, advances and prospects. <b>2018</b> , 5, HEP08		38
214	Evaluation of Chitosan Derivative Microparticles Encapsulating Superparamagnetic Iron Oxide and Doxorubicin as a pH-Sensitive Delivery Carrier in Hepatic Carcinoma Treatment: An Comparison Study. <b>2018</b> , 9, 1025		10
213	Health education helps to relieve postembolization pain during hepatic arterial chemoembolization therapy. <b>2018</b> , 11, 2115-2121		1
212	Entirely Replaced Left Gastric Artery from the Left Hepatic Artery: A Case Report. <b>2018</b> , 78, 353		
211	Near-Infrared Fluorescent Theranostic Cisplatin Prodrug with Transcatheter Intra-Arterial Therapy: Application to Rabbit Hepatocellular Carcinoma. <b>2018</b> , 1, 1800093		4
210	Transarterial Chemoembolization for Hepatocellular Carcinoma. <b>2018</b> , 37, 107-111		4

209	Chemoembolization with Vascular Disrupting Agent CKD-516 Dissolved in Ethiodized Oil in Combination with Doxorubicin: A VX2 Tumor Model Study. <b>2018</b> , 29, 1078-1084	5
208	Liver chemoembolization of hepatocellular carcinoma using TANDEM microspheres. <b>2018</b> , 14, 2761-2772	8
207	Which is the best combination of TACE and Sorafenib for advanced hepatocellular carcinoma treatment? A systematic review and network meta-analysis. <b>2018</b> , 135, 89-101	41
206	Multicentric Assessment of the Hong Kong Liver Cancer Staging System in Chinese Patients Following Transarterial Chemoembolization. <i>CardioVascular and Interventional Radiology</i> , <b>2018</b> , 41, 1867-1876 <sup>1</sup>	1
205	Drug capture materials based on genomic DNA-functionalized magnetic nanoparticles. <b>2018</b> , 9, 2870	20
204	Novel multimodal analgesia regimen improves post-TACE pain in patients with hepatocellular carcinoma. <b>2018</b> , 17, 510-516	10
203	Treatment-damaged hepatocellular carcinoma promotes activities of hepatic stellate cells and fibrosis through GDF15. <b>2018</b> , 370, 468-477	10
202	Identifying the Best Anticancer Agent Combination in TACE for HCC Patients: A Network Meta-analysis. <b>2018</b> , 9, 2640-2649	6
201	Nitroglycerine use in transcatheter arterial (chemo) embolization in patients with hepatocellular carcinoma: Five-year retrospective study. <b>2018</b> , 42, 542-552	1
200	Transarterial chemoembolization for unresectable hepatocellular carcinoma: A comparison of the efficacy and safety of 2 embolic agents. <b>2018</b> , 97, e10832	1
199	Primary Malignant Neoplasms of the Liver. <b>2018</b> , 705-729	1
198	Computed tomographic perfusion with 160-mm coverage: comparative analysis of hepatocellular carcinoma treated by two transarterial chemoembolization courses relative to magnetic resonance imaging findings. <b>2019</b> , 44, 85-94	2
197	Comparison of lipiodol infusion and drug-eluting beads transarterial chemoembolization of hepatocellular carcinoma in a real-life setting. <b>2019</b> , 54, 905-912	10
196	Combined Transarterial Chemoembolization and Percutaneous Radiofrequency Ablation: More Promising Evidence of Effectiveness in Treating Solitary, Medium-Sized Hepatocellular Carcinoma. <b>2019</b> , 30, 1545-1548	
195	Clinical Factors Predictive of a Better Prognosis of Pulmonary Metastasectomy for Hepatocellular Carcinoma. <b>2019</b> , 108, 1685-1691	8
194	Color coded perfusion imaging with contrast enhanced ultrasound (CEUS) for post-interventional success control following trans-arterial chemoembolization (TACE) of hepatocellular carcinoma. <b>2019</b> , 14, e0217599	9
193	Adjuvant transcatheter arterial chemoembolization after radical resection of hepatocellular carcinoma patients with tumor size less than 5 cm: a retrospective study. <b>2019</b> , 54, 617-622	3
192	Clinical Pharmacokinetics and Pharmacodynamics of Transarterial Chemoembolization and Targeted Therapies in Hepatocellular Carcinoma. <b>2019</b> , 58, 983-1014	13

191	Microporous drug-eluting large silk particles through cryo-granulation. <b>2019</b> , 21, 1801242		2
190	Idarubicin-loaded Beads for Chemoembolization of Hepatocellular Carcinoma: The IDASPHERE II Single-Arm Phase II Trial. <b>2019</b> , 291, 801-808		11
189	Long-term follow-up after conventional transarterial chemoembolization (c-TACE) with mitomycin for hepatocellular carcinoma (HCC). <b>2019</b> , 10, 348-353		5
188	Nomogram and Artificial Neural Network for Prognostic Performance on the Albumin-Bilirubin Grade for Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. <b>2019</b> , 30, 330-338		16
187	Dissecting the multinodular hepatocellular carcinoma subset: is there a survival benefit after hepatectomy?. <b>2019</b> , 71, 57-66		2
186	Comparing stereotactic ablative radiotherapy (SABR) versus re-trans-catheter arterial chemoembolization (re-TACE) for hepatocellular carcinoma patients who had incomplete response after initial TACE (TASABR): a randomized controlled trial. <b>2019</b> , 19, 275		7
185	Hepatocellular Carcinoma: Treatment. <b>2019</b> , 703-714		
184	Critical systematic review on hepatic resection and transarterial chemoembolization for hepatocellular carcinoma. <b>2019</b> , 15, 439-449		0
183	Current trends in the treatment of hepatocellular carcinoma with transarterial embolization: a cross-sectional survey of techniques. <i>European Radiology</i> , <b>2019</b> , 29, 3287-3295	8	21
182	Factors to transcatheter arterial chemoembolization Liver Cancer stage C. <b>2020</b> , 29, 49-55		1
181	Paclitaxel nanocrystalline assemblies as a potential transcatheter arterial chemoembolization (TACE) candidate for unresectable hepatocellular carcinoma. <b>2020</b> , 107, 110315		10
180	Utility of Contrast-Enhanced Ultrasound for Early Therapeutic Evaluation of Hepatocellular Carcinoma After Transcatheter Arterial Chemoembolization. <b>2020</b> , 39, 431-440		6
179	Intra-arterial idarubicin_lipiodol without embolization can provide prolonged complete response in hepatocellular carcinoma: A case report. <b>2020</b> , 26, 507-510		1
178	A novel treatment strategy using indocyanine green for transarterial chemoembolization in BCLC stage C hepatocellular carcinoma. <b>2020</b> , 9, 62-76		2
177	Transarterial Chemoembolisation (TACE) with Degradable Starch Microspheres (DSM) and Anthracycline in Patients with Locally Extensive Hepatocellular Carcinoma (HCC): Safety and Efficacy. <i>CardioVascular and Interventional Radiology</i> , <b>2020</b> , 43, 402-410	2.7	7
176	Sustained release of arsenic trioxide benefits interventional therapy on rabbit VX2 liver tumor. <b>2020</b> , 24, 102118		6
175	Hyperpolarized Metabolic Imaging Detects Latent Hepatocellular Carcinoma Domains Surviving Locoregional Therapy. <b>2020</b> , 72, 140-154		10
174	[Locoregional and local ablative treatment options for liver tumors]. <b>2020</b> , 61, 158-163		1

173	Design and construction of a magnetic targeting pro-coagulant protein for embolic therapy of solid tumors. <b>2020</b> , 48, 116-128		3
172	Locoregional Therapy Approaches for Hepatocellular Carcinoma: Recent Advances and Management Strategies. <i>Cancers</i> , <b>2020</b> , 12,	6.6	23
171	Role of tumor margin and ADC change in defining the need for additional treatments after the first TACE in patients with unresectable HCC. <b>2020</b> , 133, 109389		4
170	Loco-regional drug delivery in oncology: current clinical applications and future translational opportunities. <b>2021</b> , 18, 607-623		4
169	Is transcatheter arterial chemoembolization plus sorafenib better than chemoembolization plus placebo in the treatment of hepatocellular carcinoma?. <b>2021</b> , 107, 292-303		1
168	LI-RADS Imaging Criteria for HCC Diagnosis and Treatment: Emerging Evidence. <b>2020</b> , 19, 437-447		2
167	Treatment Strategy of Transarterial Chemoembolization for Hepatocellular Carcinoma. <b>2020</b> , 10, 7337		3
166	Transarterial Chemoembolization Combined with Sorafenib in Patients with BCLC Stage C Hepatocellular Carcinoma. <b>2020</b> , 14, 3461-3468		5
165	Prognostic Performance of Albumin-Bilirubin Grade With Artificial Intelligence for Hepatocellular Carcinoma Treated With Transarterial Chemoembolization Combined With Sorafenib. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 525461	5.3	7
164	Combining Chemistry and Engineering for Hepatocellular Carcinoma: Nano-Scale and Smaller Therapies. <b>2020</b> , 12,		4
163	Diagnosis, Staging, and Patient Selection for Locoregional Therapy to Treat Hepatocellular Carcinoma. <b>2020</b> , 37, 441-447		2
162	Management of patients with intermediate stage hepatocellular carcinoma. <b>2020</b> , 12, 1758835920970840		9
161	A Meta-analysis of TAE/TACE Versus Emergency Surgery in the Treatment of Ruptured HCC. <i>CardioVascular and Interventional Radiology</i> , <b>2020</b> , 43, 1263-1276	2.7	9
160	Prognostic role of alpha-fetoprotein in patients with hepatocellular carcinoma treated with repeat transarterial chemoembolisation. <b>2020</b> , 20, 483		1
159	PKM2 inhibition may reverse therapeutic resistance to transarterial chemoembolization in hepatocellular carcinoma. <b>2020</b> , 39, 99		16
158	Transcatheter Intra-Arterial Infusion Combined with Interventional Photothermal Therapy for the Treatment of Hepatocellular Carcinoma. <b>2020</b> , 15, 1373-1385		2
157	Postembolization fever after transarterial chemoembolization is a sign of unfavorable therapeutic response in hepatocellular carcinoma patients. <b>2020</b> , 7, 83-92		1
156	Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO. <b>2020</b> , 31, 334-351		64

155	Doxorubicin-loaded polyphosphate glass microspheres for transarterial chemoembolization. <b>2020</b> , 108, 2621-2632		
154	Survival analysis of 230 patients with unresectable hepatocellular carcinoma treated with bland transarterial embolization. <b>2020</b> , 15, e0227711		4
153	Trans-arterial chemoembolization with degradable starch microspheres (DSM-TACE) versus selective internal radiation therapy (SIRT) in multifocal hepatocellular carcinoma. <b>2021</b> , 62, 313-321		3
152	Standardization of conventional chemoembolization for hepatocellular carcinoma. <b>2021</b> , 22, 100278		15
151	The role of interventional radiology in the pre-liver transplant patient. <b>2021</b> , 46, 124-133		0
150	Optimizing the Combination of Immunotherapy and Trans-Arterial Locoregional Therapy for Stages B and C Hepatocellular Cancer. <i>Annals of Surgical Oncology</i> , <b>2021</b> , 28, 1499-1510	3.1	1
149	Transarterial chemoembolization of hepatocellular carcinoma before liver transplantation and risk of post-transplant vascular complications: a multicentre observational cohort and propensity score-matched analysis. <b>2021</b> , 108, 1323-1331		0
148	Hepatic Arterial Infusion Chemotherapy with Modified FOLFOX as an Alternative Treatment Option in Advanced Hepatocellular Carcinoma Patients with Failed or Unsuitability for Transarterial Chemoembolization. <b>2021</b> , 28 Suppl 1, S157-S166		2
147	Locoregional Therapies for Bridging and Downstaging Hepatocellular Carcinoma Prior to Liver Transplant. 127-144		
146	Comparison of the efficacy and safety of conventional transarterial chemoembolization with and without drug-eluting beads embolization for the treatment of unresectable large hepatocellular carcinoma. <b>2021</b> , 51, 482-489		0
145	Prediction of tumor response via a pretreatment MRI radiomics-based nomogram in HCC treated with TACE. <i>European Radiology</i> , <b>2021</b> , 31, 7500-7511	8	9
144	Duration of response after DEB-TACE compared to lipiodol-TACE in HCC-naïve patients: a propensity score matching analysis. <i>European Radiology</i> , <b>2021</b> , 31, 7512-7522	8	3
143	How to prophylactically alleviate postembolization syndrome following transarterial chemoembolization?: Protocol of a double blinded, randomized, placebo-controlled trial. <b>2021</b> , 100, e25360		0
142	Drug-eluting beads TACE is safe and non-inferior to conventional TACE in HCC patients with TIPS. <i>European Radiology</i> , <b>2021</b> , 31, 8291-8301	8	2
141	Assessing locoregional treatment response to Hepatocellular Carcinoma: comparison of hepatobiliary contrast agents to extracellular contrast agents. <b>2021</b> , 46, 3565-3578		1
140	Therapies for hepatocellular carcinoma: overview, clinical indications, and comparative outcome evaluation. Part two: noncurative intention. <b>2021</b> , 46, 3540-3548		2
139	Optimizing Loco Regional Management of Oligometastatic Colorectal Cancer: Technical Aspects and Biomarkers, Two Sides of the Same Coin. <i>Cancers</i> , <b>2021</b> , 13,	6.6	0
138	Effect of Transarterial Chemoembolization on ALBI Grade in Intermediate-Stage Hepatocellular Carcinoma: Criteria for Unsuitable Cases Selection. <i>Cancers</i> , <b>2021</b> , 13,	6.6	1

137	Recommandation opérationnelle en radiologie interventionnelle : chimioembolisation hépatique. <b>2021</b> , 4, 357-357		
136	Magnetic mesoporous embolic microspheres in transcatheter arterial chemoembolization for liver cancer. <b>2021</b> , 130, 374-384		2
135	Arterial chemoembolisation with cisplatin versus epirubicin for hepatocellular carcinoma (ACE 500 study): A multicentre, randomised controlled phase 2/3 trial. <b>2021</b> , 157, 373-382		1
134	Prospective Multi-Center Korean Registry of Transcatheter Arterial Chemoembolization with Drug-Eluting Embolics for Nodular Hepatocellular Carcinoma: A Two-Year Outcome Analysis. <b>2021</b> , 22, 1658-1670		2
133	[State of the art in the diagnostics of hepatocellular carcinoma and current treatment options]. <i>Der Radiologe</i> , <b>2021</b> , 61, 213-226	1.5	1
132	Interventional Radiology Therapies for Intrahepatic Cholangiocarcinoma. <b>2021</b> , 397-411		
131	Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. <b>2021</b> , 18, 293-313		80
130	Hepatocellular Carcinoma. <b>2010</b> , 650-660		1
129	Medical Therapy of HCC. <b>2016</b> , 489-512		1
128	Multifunctional MR Imaging Assessments: A Look into the Future. <i>Medical Radiology</i> , <b>2010</b> , 255-280	0.2	2
127	Transarterial therapies for hepatocellular carcinoma. <b>2013</b> , 190, 195-206		13
126	Chemoembolizing hepatocellular carcinoma with microsphere cored with arsenic trioxide microcrystal. <i>Drug Delivery</i> , <b>2020</b> , 27, 1729-1740	7	5
125	Gastric and duodenal ischaemia after transarterial chemoembolisation for hepatocellular carcinoma: an unexpected but significant complication. <b>2018</b> , 2018,		3
124	Assessment of hepatocellular carcinoma treatment response with LI-RADS: a pictorial review. <b>2019</b> , 10, 121		18
123	Effect of double platinum agents, combination of miriplatin-transarterial oily chemoembolization and cisplatin-hepatic arterial infusion chemotherapy, in patients with hepatocellular carcinoma: Report of two cases. <i>World Journal of Clinical Cases</i> , <b>2017</b> , 5, 238-246	1.6	2
122	Tumor angiogenesis after heated lipiodol infusion via the hepatic artery in a rabbit model of VX2 liver cancer. <b>2013</b> , 8, e61583		11
121	Use of Ethanol in the Trans-Arterial Lipiodol Embolization (TAELE) of Intermediated-Stage HCC: Is This Safer than Conventional Trans-Arterial Chemo-Embolization (c-TACE)?. <b>2015</b> , 10, e0129573		6
120	Comparison of two transarterial chemoembolization regimens in patients with unresectable hepatocellular carcinoma: raltitrexed plus oxaliplatin 5-fluorouracil plus oxaliplatin. <b>2017</b> , 8, 79165-79174		5

119	Can Kushen injection combined with TACE improve therapeutic efficacy and safety in patients with advanced HCC? a systematic review and network meta-analysis. <b>2017</b> , 8, 107258-107272	12
118	Novel implications in the treatment of hepatocellular carcinoma. <b>2017</b> , 30, 23-32	23
117	A case of necrotizing pancreatitis subsequent to transcatheter arterial chemoembolization in a patient with hepatocellular carcinoma. <b>2012</b> , 18, 321-5	18
116	Recent advances in transarterial embolotherapies in the treatment of hepatocellular carcinoma. <b>2017</b> , 23, 265-272	28
115	An uncommon cause of gastro-duodenal ulceration. <b>2008</b> , 14, 2593-5	10
114	Clinical impact of selective transarterial chemoembolization on hepatocellular carcinoma: a cohort study. <b>2009</b> , 15, 1843-8	31
113	Transarterial chemoembolization as initial treatment for unresectable hepatocellular carcinoma in southern China. <b>2010</b> , 16, 264-9	43
112	Increased extrinsic apoptotic pathway activity in patients with hepatocellular carcinoma following transarterial embolization. <b>2011</b> , 17, 4675-81	6
111	Bridging and downstaging treatments for hepatocellular carcinoma in patients on the waiting list for liver transplantation. <b>2013</b> , 19, 7515-30	80
110	Liver transplantation for hepatocellular carcinoma - factors influencing outcome and disease-free survival. <b>2015</b> , 21, 12071-82	12
109	Idarubicin doxorubicin in transarterial chemoembolization of intermediate stage hepatocellular carcinoma. <b>2020</b> , 26, 324-334	4
108	Hepatoduodenal fistula formation following transcatheter arterial chemoembolization and radiotherapy for hepatocellular carcinoma: treatment with endoscopic Histoacryl injection. <b>2014</b> , 29, 101-5	6
107	Transcatheter embolization therapy in liver cancer: an update of clinical evidences. <b>2015</b> , 27, 96-121	51
106	I Radioactive Seeds Implantation Therapy for Hepatocellular Carcinoma. <b>2009</b> , 2, 141-147	5
105	Preliminary evaluation of indigenous Y-labelled microspheres for therapy of hepatocellular carcinoma. <b>2016</b> , 143, S74-S81	4
104	Doxorubicin-loaded drug-eluting beads versus conventional transarterial chemoembolization for nonresectable hepatocellular carcinoma. <b>2015</b> , 21, 175-80	33
103	Comparison of the Efficacy of Two Microsphere Embolic Agents for Transcatheter Arterial Chemoembolization in Hepatocellular Carcinoma Patients. <b>2020</b> , 52, 24-30	6
102	Hepatocellular carcinoma Liver Imaging Reporting and Data Systems treatment response assessment: Lessons learned and future directions. <b>2020</b> , 12, 738-753	6



101	Survival rates according to barcelona clinic liver cancer sub-staging system after transarterial embolization for intermediate hepatocellular carcinoma. <b>2015</b> , 7, 628-32	15	
100	Hepatocellular carcinoma: Surgeon's view on latest findings and future perspectives. <b>2015</b> , 7, 1168-83	29	
99	DC Bead Transarterial Chemoembolization Is Effective in Hepatocellular Carcinoma Refractory to Conventional Transarterial Chemoembolization: A Pilot Study. <b>2013</b> , 7, 89-95	17	
98	Transcatheter arterial chemotherapy with miriplatin for hepatocellular carcinoma patients with chronic renal failure: report of three cases. <b>2013</b> , 7, 246-51	5	
97	Proposal of a New Risk Score for Patients Treated with Transarterial Chemoembolization due to Recurrent Hepatocellular Carcinoma after Curative Resection: A Multicenter Study. <b>2020</b> , 14, 477-485	1	
96	Repeated transcatheter arterial chemoembolization is safe for hepatocellular carcinoma in cirrhotic patients with transjugular intrahepatic portosystemic shunt. <b>2014</b> , 20, 487-91	13	
95	Impact of low versus conventional doses of chemotherapy during transcatheter arterial chemo-embolization on serum fibrosis indicators and survival of liver cancer patients. <b>2012</b> , 13, 4757-61	8	
94	Three treatment methods via the hepatic artery for hepatocellular carcinoma - a retrospective study. <b>2013</b> , 14, 2491-4	10	
93	Lobaplatin-TACE combined with radioactive 125I seed implantation for treatment of primary hepatocellular carcinoma. <b>2014</b> , 15, 5155-60	15	
92	Systematic Review of Single Large and/or Multinodular Hepatocellular Carcinoma: Surgical Resection Improves Survival. <b>2015</b> , 16, 5541-7	14	
91	Transarterial Therapies for Hepatocellular Carcinoma: a Comprehensive Review with Current Updates and Future Directions. <b>2016</b> , 17, 473-8	23	
90	In the Era of Systemic Therapy for Hepatocellular Carcinoma Is Transarterial Chemoembolization Still a Card to Play?. <i>Cancers</i> , <b>2021</b> , 13,	6.6	o
89	European Multicenter Study on Degradable Starch Microsphere TACE: The Digestible Way to Conquer HCC in Patients with High Tumor Burden. <i>Cancers</i> , <b>2021</b> , 13,	6.6	o
88	Medical Therapy of HCC. <b>2009</b> , 527-568		
87	Chemoembolization, Radioembolization and Other Novel Intra-arterial Therapies. <b>2009</b> , 124-133		
86	Which treatment modality should we choose for advanced hepatocellular carcinoma?. <b>2010</b> , 16, 353-4		
85	Efficacy of Novel Transcatheter Arterial Therapy for Hepatocellular Carcinoma. <b>2011</b> , 60, 173-178	1	
84	Interventional approaches to treatment in supportive oncology. <b>2011</b> , 382-389		

- 83 Emerging Therapies for Hepatocellular Carcinoma. **2012**, 263-290
- 82 Recurrence: Prevention and Management. **2012**, 215-227
- 81 Current Status of Hepatocellular Carcinoma Treatment in Japan. **2012**, 32, 3-13
- 80 Liver and Biliary Tract Carcinoma Surveillance Counterpoint: Canada. **2013**, 169-178
- 79 Induktionschemotherapie bei hepatozellulären Karzinomen. **2013**, 225-236
- 78 Transvaskuläre Therapie des hepatozellulären Karzinoms. **2013**, 299-322 1
- 77 Hepatic Tumors: An Oncologist's Perspective. 273-282
- 76 Tumor Embolization: Embolization of Liver Tumors. **2014**, 897-903
- 75 Hepatic arterial embolization with glycolic acid-ethylcellulose microspheres in treatment of hepatic tumor in rabbits. **2013**, 32, 954-958
- 74 Interventional Radiology in Oncology. **2014**, 43-63
- 73 Aspects post-thérapeutiques des carcinomes hépatocellulaires. **2014**, 137-166
- 72 Interventional Radiology for the Pre-Transplant Patient. **2016**, 1-12
- 71 Interventional Radiology for the Pre-Transplant Patient. **2016**, 1-12
- 70 Comparison of the Local Control Effects of Microballoon-Occluded Transarterial Chemoembolization (TACE) Using Miriplatin and Using Epirubicin for Hepatocellular Carcinoma: A Retrospective Study of 62 Cases. **2017**, 2, 64-73 0
- 69 Effects of Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma Using a Combination of Platinum Agents (Cisplatin plus Miriplatin): A Retrospective Comparison with Cisplatin Monotherapy. **2018**, 08, 260-273
- 68 Lebertumoren. **2018**, 397-441
- 67 Hepatocellular Carcinoma. **2018**, 668-692.e9 1
- 66 Management of ruptured liver segment IV hepatocellular carcinoma: is transarterial embolization (TAE) superior to chemoembolization (TACE)?-the jury is still out. **2018**, 6, 272 0

65	Transarterial Embolization Therapies in Hepatocellular Carcinoma: Principles of Management. <b>2019</b> , 123-138		1
64	Role of Interventional Radiology in Management of Gastrointestinal Cancers and Neuroendocrine Tumors. <b>2019</b> , 551-572		
63	Necrosis of Hepatocellular Carcinoma Caused by Iatrogenic Hepatic Artery Dissection during Transcatheter Arterial Chemoembolization. <b>2019</b> , 80, 562		
62	The Management of Hepatocellular Carcinoma. <b>2020</b> , 237-271		0
61	Transcatheter arterial chemoembolization combined with microwave ablation for treatment of early liver cancer: Efficacy and prognostic factors for progression-free survival. <b>2019</b> , 27, 1201-1208		
60	Regional Therapies in Hepatocellular Carcinoma and Cholangiocarcinoma. <b>2020</b> , 311-322		
59	Cancer primitif du foie (carcinome hépatocellulaire). <b>2020</b> , 218-226.e3		
58	Impact of tumor anatomic characteristics on patient radiation dose during transarterial chemoembolization. <i>American Journal of Interventional Radiology</i> , 4, 5		
57	Paraplegia after transcatheter artery chemoembolization in a child with clear cell sarcoma of the kidney: A case report. <i>World Journal of Clinical Cases</i> , <b>2020</b> , 8, 2332-2338	1.6	1
56	Treatment of Hepatocellular Carcinomas by Hepatic Transarterial Chemoembolization, Case Presentation and Review of the Literature. <i>Acta Medica Transilvanica</i> , <b>2020</b> , 25, 32-35	0	
55	Report from the Western Canadian Gastrointestinal Cancer Consensus Conference Virtual Education Series-Transition from Local to System Therapy and Optimal Sequencing of Systemic Therapy for HCC.. <i>Current Oncology</i> , <b>2021</b> , 28, 4317-4327	2.8	0
54	Comparison of metabolic and immunologic responses to transarterial chemoembolization with different chemoembolic regimens in a rabbit VX2 liver tumor model. <i>European Radiology</i> , <b>2021</b> , 1	8	1
53	Chemoembolization for Hepatocellular Carcinoma. <b>2020</b> , 282-286.e2		
52	Physics and Physiology of Transarterial Chemoembolization and Drug-Eluting Beads for Liver Tumors. <b>2020</b> , 29-42		
51	Transarterial Chemoembolisation and Combined Therapy. <i>Medical Radiology</i> , <b>2021</b> , 283-317	0.2	
50	Onkologische Embolisierung. <b>2021</b> , 409-504		
49	A multidisciplinary approach to the management of hepatocellular carcinoma. <i>Gastroenterology and Hepatology</i> , <b>2010</b> , 6, 1-16	0.7	7
48	Liver abscess as a complication of hepatic transarterial chemoembolization: a case report, literature review, and clinical recommendations. <i>Gastrointestinal Cancer Research: GCR</i> , <b>2009</b> , 3, 247-51		2

47	Transarterial chemoembolization with Doxorubicin-eluting microspheres for inoperable hepatocellular carcinoma. <i>Gastrointestinal Cancer Research: GCR</i> , <b>2011</b> , 4, 2-8		10
46	Prognostic factors for acute kidney injury following transarterial chemoembolization in patients with hepatocellular carcinoma. <i>International Journal of Clinical and Experimental Pathology</i> , <b>2014</b> , 7, 2579-86	1.4	12
45	Doxorubicin-eluting beads versus conventional transarterial chemoembolization for the treatment of hepatocellular carcinoma: a meta-analysis. <i>International Journal of Clinical and Experimental Medicine</i> , <b>2014</b> , 7, 3892-903		13
44	Nanocomposite Carriers for Transarterial Chemoembolization of Liver Cancer. <b>2016</b> , 4, E173-E182		1
43	Comparison of treatment efficacy and safety between drug-eluting bead transarterial chemoembolization with CalliSpheres microspheres and conventional transarterial chemoembolization as first-line treatment in hepatocellular carcinoma patients. <i>American Journal of Translational Research (discontinued)</i> <b>2019</b> , 11, 7156-7170	3	13
42	Antitumor properties of arsenic trioxide-loaded CalliSpheres microspheres by transarterial chemoembolization in VX2 liver tumor rabbits: suppression of tumor growth, angiogenesis, and metastasis and elongation of survival. <i>American Journal of Translational Research (discontinued)</i> , <b>2020</b> , 12, 5511-5521	3	1
41	Limitations and Possibilities of Transarterial Chemotherapeutic Treatment of Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	0
40	Initial outcomes of mitomycin intravascular chemoembolization (MICE) for corneal neovascularization.. <i>International Ophthalmology</i> , <b>2022</b> , 1	2.2	1
39	Endovascular treatment of common hepatocellular carcinoma: the experience of one center. <i>Ukrainska Interventivna Nejrroadiologija Hirurhija</i> <b>2022</b> , 37, 57-61		
38	VueBox for quantitative analysis of contrast-enhanced ultrasound in liver tumors.. <i>Clinical Hemorheology and Microcirculation</i> , <b>2021</b> ,	2.5	1
37	[Transarterial chemoembolization of hepatocellular carcinoma].. <i>Der Radiologe</i> , <b>2022</b> , 62, 225	1.5	0
36	Table_1.DOCX. <b>2018</b> ,		
35	Video_1.MP4. <b>2018</b> ,		
34	Table_1.docx. <b>2020</b> ,		
33	Precision medicine approaches for treating hepatocellular carcinoma. <b>2022</b> , 287-299		
32	Combination of interventional oncology local therapies and immunotherapy for the treatment of hepatocellular carcinoma. <i>Journal of Liver Cancer</i> ,	0.7	1
31	Immunotherapy-Based Treatments of Hepatocellular Carcinoma: Expert Panel Narrative Review.. <i>American Journal of Roentgenology</i> , <b>2022</b> ,	5.4	1
30	Interventional Radiology of the Liver. <b>2015</b> , 1498-1519		

29	Intratumoral Pi deprivation benefits chemoembolization therapy via increased accumulation of intracellular doxorubicin. <i>Drug Delivery</i> , <b>2022</b> , 29, 1743-1753	7	0
28	Multidisciplinary collaboration for the successful treatment of a giant hepatic solitary fibrous tumor protruding into the thorax: A case report. <i>Experimental and Therapeutic Medicine</i> , <b>2022</b> , 24,	2.1	
27	Liver biopsy technique in the era of genomic cancer therapies: a single-center retrospective analysis. <i>International Journal of Clinical Oncology</i> ,	4.2	
26	Ruptured Hepatocellular Carcinoma: What Do Interventional Radiologists Need to Know?. <i>Frontiers in Oncology</i> , 12,	5.3	1
25	Transparent Liver Tumor as an Ex Vivo Model for Transarterial Chemoembolization (TACE). <i>SSRN Electronic Journal</i> ,	1	
24	Intraarterial Therapies for the Management of Hepatocellular Carcinoma. <i>Cancers</i> , <b>2022</b> , 14, 3351	6.6	1
23	Precision Imaging Guidance in the Era of Precision Oncology: An Update of Imaging Tools for Interventional Procedures. <i>Journal of Clinical Medicine</i> , <b>2022</b> , 11, 4028	5.1	1
22	Recurrence of Hepatocellular Carcinoma After Complete Radiologic Response to Trans-Arterial Embolization: A Retrospective Study on Patterns, Treatments, and Prognoses. <i>Annals of Surgical Oncology</i> ,	3.1	0
21	Transarterial Infusion Chemotherapy With and Without Embolisation in Hepatocellular Carcinoma Patients: A Systematic Review and Meta-Analysis. <b>2017</b> , 46, 174-184		1
20	Identification of predictive factors for post-transarterial chemoembolization liver failure in hepatocellular carcinoma patients: A retrospective study. <b>2022</b> , 10, 8535-8546		
19	Zytostatikabeschichtete Beads. <b>2022</b> , 1-8		0
18	Indian College of Radiology and Imaging Guidelines on Interventions in Hepatocellular Carcinoma.		0
17	Drug Delivery in Transarterial Chemoembolization of Hepatocellular Carcinoma: Ex vivo Evaluation Using Transparent Tissue Imaging. <b>2022</b> ,		0
16	Simultaneous treatment with sorafenib and glucose restriction inhibits hepatocellular carcinoma in vitro and in vivo by impairing SIAH1-mediated mitophagy.		1
15	Stereotactic Radiotherapy after Incomplete Transarterial (Chemo-) Embolization (TAETACE) versus Exclusive TAE or TACE for Treatment of Inoperable HCC: A Phase III Trial (NCT02323360). <b>2022</b> , 29, 8802-8813		0
14	Mortality evaluation and life expectancy prediction of patients with Hepatocellular carcinoma with data minding.		0
13	Oncopharmacology in Interventional Radiology. <b>2022</b> , 39, 411-415		0
12	Nonsurgical Treatment for Localised Hepatocellular Carcinoma. 69-75		0

- 11 ACR Appropriateness Criteria<sup>®</sup> Management of Liver Cancer: 2022 Update. **2022**, 19, S390-S408 ○
- 10 Evaluation of Transarterial Chemoembolization Protocol with Drug-Eluting Beads in Combination with Lipiodol for Hepatocellular Carcinoma: A Single-Center Controlled Study. **2022**, 2022, 1-10 ○
- 9 Identifying optimal candidates for post-TIPS patients with HCC undergoing TACE: a multicenter observational study. ○
- 8 Pathogenesis and Current Treatment Strategies of Hepatocellular Carcinoma. **2022**, 10, 3202 1
- 7 Drug-eluting Microspheres Compared to Conventional Transarterial Chemoembolization as First Line Treatment for Unresectable Hepatocellular Carcinoma: A Single-center Retrospective Cost-utility Analysis. ○
- 6 Syngeneic N1-S1 Orthotopic Hepatocellular Carcinoma in Sprague Dawley Rat for the Development of Interventional Oncology-Based Immunotherapy: Survival Assay and Tumor Immune Microenvironment. **2023**, 15, 913 ○
- 5 Therapeutic options in hepatocellular carcinoma: a comprehensive review. ○
- 4 Effectiveness of c-TACE Combined With Sorafenib Versus c-TACE Monotherapy in Advanced Hepatocellular Carcinoma: A Retrospective Study. **2023**, 17, 117955492211466 ○
- 3 Clinical consensus statement: Establishing the roles of locoregional and systemic therapies for the treatment of intermediate-stage hepatocellular carcinoma in Canada. **2023**, 115, 102526 ○
- 2 Mortality Evaluation and Life Expectancy Prediction of Patients with Hepatocellular Carcinoma with Data Mining. **2023**, 11, 925 ○
- 1 TACE for HCC : A critical review of the 2021 CIRSE recommendations with presentation of a technique for a degradable starch microsphere<sup>®</sup>TACE. ○